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FOREWORD
This program was undertaken to evaluate possible interactions
among drugs contemplated for use during manned space flights. It was
carried out during the period July 1, 1972 to September 30, 1973 and
was the subject of our proposals dated March 10, 1972 and May 14, 1973,
in response to RFP No. 9-13B32-79-2-185P and RFP No. 9-13B631-4-3177P.
The program will continue until June 30, 1974.
Dr. Vernon Carter of the NASA Manned Spacecraft Center is
Technical Officer for this agency. Dr. David W. Yesair, Dr. Francis J.
Bullock (former Arthur D. Little, Inc. staff member), Dr. Philip S. Thayer,
Mrs. Marianne Callahan, and Mr. James Braun comprise the Arthur D. Little,
Inc., project team.
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SUMMARY
Possible interactions among drugs contemplated for use during
manned spaceflights have been studied in several animal species. The
following seven drugs were investigated: nitrofurantoin, chloral hydrate,
hexobarbital, phenobarbital, flurazepam, diphenoxylate, and phenazopyridine.
Particular combinations included: chloral hydrate, hexobarbital or
flurazepam with nitrofurantoin; phenobarbital or flurazepam with phenazo-
pyridine; and diphenoxylate with two dose formulations of nitrofurantoin.
Specifically, rat liver microsomes were used to determine whether
chronic dosage with nitrofurantoin would inhibit rates of oxidative drug
metabolism. Rates of hexobarbital oxidation, N-demethylation of meperidine,
and reduction of p-nitrobenzoic acid were studied in control and nitro-
furantoin-treated rats. No difference in oxidative metabolic rates were
found between control and nitrofurantoin-treated rats.
Pharmacological studies were carried out to determine whether
premedication of rats with nitrofurantoin would result in potentiation
of activity of hexobarbital, chloral hydrate, or flurazepam. This was
determined for chloral hydrate and hexobarbital by studies of sleeping
times determined by loss of the righting reflex. Flurazepam was
investigated by use of the inclined screen test. No potentiation of
activity was found between control and nitrofurantoin-treated animals.
Studies were carried out in several species to determine whether
induction of liver microsomal enzymes would increase the tendency of
phenazopyridine to produce methemoglobin in vivo. Animals were pre-
medicated with phenobarbital, a known inducer of azoreductase, and in a
separate experiment with flurazepam, before administration of phenazo-
pyridine. Methemoglobin production was determined in each animal after
receiving phenazopyridine. No evidence was found for increased production
of methemoglobin in the rat, dog, or rabbit that could be attributed to
increased amounts of microsomal enzymes.
PRECEDING PAGE BLANK NOT FILMED
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The final group of experiments was conducted to determine whether
premedication of the dog with diphenoxylate would result in altered bio-
availability of Furadantin or Macrodantin®. The rate of drug excretion
in the urine was determined and a plot of percent drug absorbed versus
time was constructed for each dosage form, with and without diphenoxylate
pretreatment. Drug in the urine was determined by both chemical and
microbiological methods. Two doses of diphenoxylate were studied in four
female beagles with each dog serving as its own pre-diphenoxylate control.
Diphenoxylate was found to alter substantially the excretion pattern of
both forms of nitrofurantoin, generally increasing total absorption.
On the basis of this work, the present contract was extended
to include nitrofurantoin/diphenoxylate studies in man. The clinical
study was carried out by Medical and Technical Research Associates, Inc.,
Needham, Massachusetts. Six subjects received both dosage forms of
nitrofurantoin alone, and in combination with diphenoxylate. The results
of these studies are inconclusive. The mechanism of action and an
explanation of the interaction between diphenoxylate and nitrofurantoin
still remains unclear. In man, the interaction does not appear to be
significant, affecting only two subjects out of six and with only one
dose formulation (Furadantin .
4
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I. INTRODUCTION
The general approach to the use of drugs by astronauts during
space flights has been cautious, but in-flight medical problems requiring
their use have occurred. With the advent of the Sky Lab program, the
probability that astronauts may find it necessary to take one or more of
the drugs carried in their medical kits greatly increases. As has been
reviewed elsewhere,l results of epidemiological studies of adverse drug
effects were of great consequence in bringing attention to drug inter-
actions. Of particular importance, a direct relationship between the
number of drugs used and the probability of adverse drug reactions clearly
emerged from these studies. Unquestionably, use of drugs in combination
carries with it an increased probability of an adverse drug effect.
Adequate clinical data on risk/benefit ratios for particular
drugs are just now beginning to emerge. Similar data for drugs used in
combination are generally unavailable. The relative probabilities for
therapeutic mishap are highest for antimicrobials, cardiac drugs, and
hypnotics and sedatives. These classes are all heavily represented in
the list of drugs now contemplated for possible use during manned space
flight. With the Sky Lab program involving longer residence for astronauts
in space, this project was concerned with the increased possibility that
drugs would be taken in combination, with unknown effects.
5
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II. BACKGROUND
A. Studies of Potential Interactions between Nitrofurantoin and
Chloral Hydrate, Barbiturate, or Flurazepam In Vitro and In Vivo
Nitrofurantoin
Nitrofurantoin (I) is one of several nitrofuran derivatives possess-
ing antibacterial activity. It is used exclusively as a urinary antiseptic.
2 CH=N-NLJ
I
Nitrofurantoin (Furadantin, Macrodantir , sulfisoxazole (Gantrisin, and
sulfamethoxazole (Gantanop are frequently considered to be therapeutic
equivalents in the treatment of urinary tract infections.2 A recent study
determined specific reaction rates for adverse effects with these three drugs
in hospitalized patients.2 Where a urinary antiseptic was indicated,
patients were treated with one of these three drugs on a random basis.
For our purposes, it is significant that adverse reaction rates in this
group were highest for nitrofurantoin - 5.1%. Incidence of adverse effects
was dose dependent and dependent on the duration of treatment, suggesting
a correlation with increased blood levels. Reaction frequently was manifest
in nausea and vomiting. The higher incidence of reactions to nitrofurantoin,
relative to sulfisoxazole suggests further study with it is appropriate.
A variety of enzymes are known to be inhibited by nitrofurans
in vitro.3'4 These enzymes are involved in redox reactions and include
nitroreductase, glutathione reductase, and, of particular interest,
aldehyde dehydrogenase.5 Inhibition of such enzymic reactions is, in fact,
thought to be intimately involved in the mechanism of action of these
compounds.5
PRECEDING PAGE BLANK NOT FILMED
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Chloral Hydrate
The metabolism of chloral hydrate is reasonably well known in
man.6 The drug is rapidly converted, in a reaction catalyzed by alcohol
dehydrogenase, to the believed active drug, trichloroethanol. Trichloro-
ethanol is partially excreted in urine as its glucuronide, but is also
slowly oxidized to trichloroacetic acid which slowly accumulates in plasma.
This oxidation occurs largely in liver and kidney and is known to be
NAD-dependent. Trichloroacetic acid is tightly bound to plasma protein
and only slowly excreted.7 The known metabolic fate of chloral hydrate
is summarized in Figure 1. By analogy with the conversion of ethanol to
acetate, the conversion of trichloroethanol to trichloroacetate likely
involves both alcohol dehydrogenase and an aldehyde dehydrogenase.
In view of the above described inhibitory activity of nitro-
furantoin on an aldehyde dehydrogenase, it seems to us not unreasonable
that this drug may inhibit metabolism of trichloroethanol and thereby
prolong its action.
Barbiturate
It has also been reported in a rather obscure paper8 that
nitrofurantoin (100 or 200 mg/kg) potentiates the sleeping time produced
by hexobarbital in the rat. The mechanism of this potentiation is
unknown, but it again seems not unreasonable that inhibition of oxidative
metabolism of the barbiturate may be involved. As the average daily oral
dose of nitrofurantoin in humans is 5-10 mg/kg, the dose used in the above
study may be unrealistically high. Using dosage conversion factors suggested
by Freireich et aZ.,9 a dose for the rat, which is comparable to 5-10 mg/kg
in the human, should be in the range 35-70 mg/kg, not the 100-200 mg/kg
reportedly used. Freireich's conversion factors are used for estimating
dosage equivalency on the basis of mg/m2 of body surface area, rather than
body weight.
8
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OH alcohol rC1 CC C1 C-CH OH C1 CC3 H\ OH dehydrogenase 3C 2 3 \ OH
glucuronide
FIGURE 1
Metabolism of chloral hydrate
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Flurazepam
The rationale for including flurazepam (II) here is, in part,
merely to complete this set of experiments with the third operational
sedative drug. Flurazepam is a relatively new drug. These experiments
CH2CH2N
Cl N
/\ F
II
should help shed some light on the possible mechanisms involved in the
drug's action and metabolism. The route of metabolism of nitrofurantoin
is unknown so that the possibility of chronic dosing with nitrofurantoin,
affecting the way rats responded to flurazepam, was speculative.
The metabolism of flurazepam has only recently been worked out
in detail.10 The major metabolite is III in man and IV in dog, and
metabolism is very rapid.
CH CHH20H CH2CO2H
I A 0 1 o
N N
F F
III IV
A likely scheme accounting for these metabolites is shown in Figure 2.
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II mi
CH2CH20H CH2 CH= amine
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minor route
H 0
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FIGURE 2
Proposed metabolism of flurazepam
If one assumes an N-dealkylation, then invokes an amine oxidase catalyzed
conversion to a hypothetical aldehyde, as shown, one can account for the
major metabolites of flurazepam in both species.
The route of metabolism of nitrofurantoin is unknown, but a variety
of mammalian tissues are known to metabolize nitrofurans. 1 1 ,1 2 Metabolism
appears to involve a reductive transformation, but the drug is not metabolized
in vitro by nitro reductase from guinea pig microsomes.4 If reduction of
nitro is excluded, there are few alternative reductive transformations possible
with this molecule.
We do not know a precedent for enzymic reduction of a Schiff base by
microsomes. One alternative to nitro group reduction is indicated below.
9N CH=N-N -ON CH-N 
V
Remotely related may be the NADPH-dependent reduction of VI by a reductase
13known to be present in dog erythrocytes.
0 0II reductase 11
CH=CHCCH 3  2CH2CH2CCH3
VI
What would be of interest about the highly speculative transformation
of nitrofurantoin to V is that the product (V) is closely related to an
acyl hydrazide. Many acyl hydrazides, for example, isocarboxazid, (Marplan ,
VII) are potent inhibitors of monoamine oxidase, an enzyme which may be
involved in the metabolism of flurazepam.
0
II
CH2NHN HNIC
'/ CH3
VII
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To determine whether nitrofurantoin can potentiate the action of
chloral hydrate, to determine if the reported potentiation of barbiturate
action by nitrofurantoin occurs at more reasonable doses, and to study the
potential interaction between nitrofurantoin and flurazepam, we carried
out the following.
(a) Male rats (100-150 g) were given daily oral doses of
nitrofurantoin (72 mg/kg) for periods of up to 7 days in three equally
divided doses. Nitrofurantoin can be expected to be used on such a chronic
dosage schedule. Sleeping times produced by i.p. dosage of chloral hydrate
and hexobarbital were determined and compared with control groups not
dosed with nitrofurantoin. Since flurazepam did not produce a "sleeping
time" as it is usually defined, the inclined screen test was used to evaluate
the potential interaction between nitrofurantoin and flurazepam.
(b) To determine whether chronic dosage of nitrofurantoin can
result in inhibition of oxidative hepatic drug metabolism, the following
experiments were carried out. On the seventh day of the above described
dosage regimen, we characterized the barbiturate oxidase and meperidine
N-demethylase of rat liver microsomes from the nitrofurantoin and control
groups of rats. We proposed to use meperidine rather than flurazepam
itself for probing N-dealkylation in vitro since acetaldehyde, one product
of N-de-ethylation of flurazepam, is not as readily determined as formaldehyde.
To complete the profile, we determined microsomal nitroreductase and
cytochromes P-450 and b 5 after treatment of animals with nitrofurantoin.
While there is not now any evidence that nitrofurantoin or
nitrofurans can act as enzyme inducers the design of this experiment
additionally provided information on this point. The idea that an enzyme
inhibitor can also be an inducer of biosynthesis of the enzyme is not new.
7,8-Benzoflavone is both an inducer and an inhibitor in vitro of benzpyrene
hydroxylase in the mouse.14
13
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B. Studies of Potential Interactions of Enzyme Inducers with
Phenazopyridine.
Phenazopyridine (VIII) is an old drug, developed in the 1930's
as a urinary antiseptic. It is now used as a urinary tract anesthetic,
either alone (Pyridium( , Warner-Chilcott Laboratories) or in combination
with sulfonamides [as in Azo-Gantrisin(' Thiosylfil-A (Lederle Laboratories),
Azo Gantanol (Roche Laboratories), Azo Kynex® (Lederle Laboratories)].
Methemoglobinemia is frequently produced by the drug;1 5 more rarely, it
may produce hemolytic anemia.1 6 ,1 7 Accidental overdosage with phenazopyridine
has led to production of large amounts of methemoglobin and cyanosis. 1 8
A dose of 200 mg/kg, admittedly quite high, produced anemia in the dog.1 9
H2N N NH2
VIII
The metabolism of phenazopyridine has apparently never been
studied, but there is ample analogy for the suggestion that it will be
metabolized by azoreductase. For example, the transformations of neoprontosil,
salicylazosulfapyridine (Azulfidine and azobenzene indicated below are
particularly well known.
0
CH3CN N=-N so 2NH2
I azo reductase H2N - \ SO2NH2HO3  SO 3H
Neoprontosil Sulfanilamide
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0azo reductase
Salicylazosulfapyridine Sulfapyridine
NH2
/N=N azo reductase 2
Azobenzene Aniline
While phenazopyridine apparently can, by itself, produce methemoglobin
in vitrol6 the products of reduction of the azo linkage should be much
more potent in producing methemoglobin, as illustrated below. Aniline is
one of the most potent methemoglobin producers known.2 0 It requires
metabolic activation for this action, the active agent apparently being
the quinone imine. 2 0 The process is detailed below.
2 2
OH 0
NH NH2
N N I N N
+ 2 Fe + Fe+ 3
N N
Hb OH MHb
[o] etc.
A similar cycle can be constructed for 2,3,6-triaminopyridine, the other
product of reduction of phenazopyridine, as also shown.
15
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H2N
2 N NH 2  HN N NH2
NH [oH NH2
NH 2
H N NH2  2N N -------
+ 2 Fe+2  +2 Fe
[o] etc.
Production of some methemoglobin by a drug is ordinarily not an
important clinical problem, but impairment of any of the oxygen transport
capacity of individuals subject to extreme physical exertion may be another
matter. Azo reductase is an inducible enzyme and our interest here is
whether the presence of enzyme inducers will tend to increase formation of
methemoglobin by phenazopyridine. We proposed the following but due to lack
of any interaction, we deleted several aspects of this program.
Phenobarbital
This drug is already known to induce azoreductase in the rat21
and other species including humans. The older literature20 suggests the
cat for work with methemoglobin formers. In our experience, healthy cats
are not easy to procure for experimental purposes and are a favorite species
of the antivivisectionists. Accordingly, we proposed to use the rabbit
and the rat for this study. Liver azoreductase has been demonstrated in
both species.22 Upon subsequent evaluation of these species as methemoglobin
formers, we found they were poor and used the dog as the species of choice for
this work.
16
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Azoreductase was induced by daily administration of phenobarbital
for not less than three days. Phenazopyridine was then administered to
control and phenobarbital-treated animals. Periodically, blood samples
were taken and methemoglobin determined. As a measure of change in
overt toxicity of phenazopyridine as a result of premedication with
phenobarbital, LD50 for phenazopyridine in the rat were planned in
control and barbiturate-treated animals, but not completed.
Flurazepam
Induction of drug metabolizing enzymes by flurazepam has not
been reported, but flurazepam is still a relatively new drug. The closely
related drugs, diazepam and chlordiazepoxide, will induce microsomal enzymes
in the rat.23 The particular enzymes shown to be inducible in this study2 3
were an O-demethylase (substrate = p-nitroanisole), an aryl hydroxylase
(substrate = aniline), and an N-demethylase (substrate = amidopyrine).
We proposed to carry out the experiment described above for
phenobarbital with flurazepam. Possible increase of methemoglobin from
phenazopyridine was studied after chronic administration of flurazepam
to rats and guinea pigs but the latter study was not performed. Determination
of LD5 0 for phenazopyridine in control and flurazepam-treated rats were
also planned but not carried out. In view of the fact that nothing is
known about the enzyme-inducing properties of flurazepam, we determined
whether microsomal azoreductase is induced by this drug. In addition,
we carried out determinations of cytochrome P-450 and b5 in control and
flurazepam-treated rats.
C. Study of the Effect of Diphenoxylate on the Bioavailability of
Nitrofurantoin.
In our previous program for NASA, we have studied the effect of
spacecraft environment on drug metabolism and on the pharmacological
activity of drugs (Contract NAS 9-9806). Generally, we have concluded
17
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that most drugs under spacecraft environment had no significant adverse
effects. However, diphenoxylate does appear to alter the pharmacokinetics
of at least two drugs.
In our first NASA-sponsored studies, diphenoxylate potentiated
the secobarbital- and, to a lesser extent, hexobarbital-induced sleeping
times in rats. Diphenoxylate had been given 16-18 hr prior to the
barbiturates. Barbiturate metabolism by liver microsomes in vitro was
unchanged in diphenoxylate-treated rats compared to control animals and
the potentiation does not appear to involve inhibition of barbiturate
metabolism by diphenoxylate.
Diphenoxylate has been shown to be extensively metabolized in
rats, dogs, and man.1,2 4',2n bile-cannulated rats, 90% of the administered
label was recovered in the bile.25 The major excretory pathway is the
feces and the rate of fecal excretion of the metabolites is slow. Thus,
the extensive biliary secretion and slow fecal excretion is consistent
with having an enterohepatic cycle for diphenoxylate and its metabolites.
A metabolite of diphenoxylate, difenoxine (R 15403), has been shown to
be responsible for the pharmacological activity associated with diphenoxy-
26-29 2 6
-
2 9
late 26-29 and the pharmacokinetics of difenoxine in man and animals
are similar.
The striking feature of the drug interaction between diphenoxylate
and barbiturates in rats was the 16 hr between dosing the two drugs. If
diphenoxylate enters an enterohepatic cycle, then one would expect a
long biological half-life of the active component in both animals. Thus,
any interaction between diphenoxylate and a second drug, many hours after
the diphenoxylate treatment, could reasonably be expected.
Since diphenoxylate decreases G.I. motility, an increased
absorption of secobarbital probably is due to the increased residence
time of the drug in the G.I. tract. This was, in part, documented by
finding an increased total Cxt of secobarbital in plasma of rats
18
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(NASA-Final Report, Contract NAS 9-9806), but other factors must also be
important, especially since hexobarbital was given intraperitoneally in
the hexobarbital/diphenoxylate interaction study.
The increased sleeping time with the hexobarbital/diphenoxylate
drug combination was less than that for the secobarbital/diphenoxylate
study. The rate of metabolism of hexobarbital is rapid compared to
secobarbital in the rat. Diphenoxylate apparently did not grossly affect
the overall rate of hexobarbital metabolism (NASA Final Report, Contract
NAS 9-9806). Therefore, the rate that the drug is metabolized might also
play an important role in the overall expression of the diphenoxylate
interaction. Specifically, even if diphenoxylate results in an increased
absorption of a drug, if such a drug were rapidly metabolized, one might
not see an enhanced pharmacological effect. It is this possibility that
might explain the absence of any diphenoxylate/chloral hydrate interaction
in the rat (NASA Final Report, Contract NAS 9-9806).
Nitrofurantoin
Nitrofurantoin is marketed in two solid dosage forms, micro-
crystalline in a tablet (Furadantin s , Eaton Laboratories) and macro-
crystalline in capsules (Macrodantin , Eaton Laboratories). Oral
absorption of these dosage forms has been studied by following urinary
excretion of drug in the dog,30 although detailed kinetics were not
determined. It was established that the rate of absorption of these two
crystalline forms of nitrofurantoin is different, the macrocrystalline
30
form being more slowly absorbed. It has also been established that
with the macrocrystalline dosage form, the amount of antibiotic excreted
in urine is less than that found with the microcrystalline form during
the first 24 hr after the first dose. It. was noted, however, that urinary
antibiotic exceeded minimum effective antibacterial levels with both
dosage forms. Use of diphenoxylate, which decreases intestinal motility,
may further affect the rate of absorption of nitrofurantoin, especially
the macrocrystalline form (Macrodantin .
19
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It is possible to determine the percent of drug absorbed with
time by following the kinetics of urinary excretion. Before describing
the experiments, it seems well to present the manner in which urinary
excretion data can provide quantitative information on rate and amount of
drug absorption.31
The time course of nitrofurantoin in plasma after intravenous
injection suggests a simple one-compartment open model is adequate for
describing the kinetics of this drug. That is, a model such as that in
Figure 3 should be adequate for treating the kinetics of drug excreted
in urine after an oral dose. After a single dose, the amount of unchanged
drug appearing in urine with time typically follows a course like
that of Figure 4.
It may be shown 31 that the fraction (percent) of an oral dose absorbed
at a time T (fDo) follows the expression:
/ = (dXu/dt + X
fDo = X 100(Xu).,
Xu, is the amount of drug ultimately excreted in urine after a single dose.
Xu is the amount eliminated up to a time T. Reliable estimation of Xu.
requires that urine be collected for eight to ten times the biological half-
life of the drug. The differential, d(Xu/dt) is obtained from the slope
of the plot of total unchanged drug excreted in urine versus time (Figure 4).
Kel is the overall rate constant for elimination of drug. KeZ may be
evaluated by plotting ln(Xu,, - Xut) from the "tail end" of the plot in
Figure 4 versus time. This gives all the elements needed for solution of
the equation and, consequently, a plot of "Fraction of Oral Dose Absorbed
vs. Time" may be constructed. This is a procedure commonly used to determine
bioavailability of drugs. Blood levels may be similarly used, but in the
case of nitrofurantoin, available analytical methods appear insufficiently
sensitive for work at the dose involved.
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FIGURE 3
Model for rate of appearance of unchanged drug in urine
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Studies to determine the effect of diphenoxylate on the bio-
availability of nitrofurantoin have been carried out in dogs and man.
In view of the pur ose of this study, we used the commercial dosage
forms, Furadantin and Macrodantin rather than bulk drug. These
studies were done using four female dogs and six male subjects. The
rate of absorption of antibiotic and total antibiotic absorbed will be
compared in each group and with each dosage form.
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III. RESULTS
A. Studies of Potential Interaction between Nitrofurantoin and
Chloral Hydrate, Barbiturates, or Flurazepam In Vitro and
In Vivo.
1. Summary
Rat liver microsomes were used to determine whether chronic
dosage with nitrofurantoin would inhibit rates of oxidative drug
metabolism. Rates of hexobarbitaloxidation, N-demethylation of
meperidine, and reduction of p-nitrobenzoic acid were studied in
control and nitrofurantoin-treated rats. No difference in oxidative
metabolic rates was found between control and nitrofurantoin-treated
rats.
Pharmacological studies were carried out to determine whether
premedication of rats with nitrofurantoin would result in potentiation
of activity of hexobarbital, chloral hydrate, or flurazepam. This was
determined for chloral hydrate and hexobarbital by studies of sleeping
times determined by loss of the righting reflex. Flurazepam was investi-
gated by use of the inclined screen test. No potentiation of activity
was found between control and nitrofurantoin-treated animals.
2. Introduction
Nitrofurantoin is one of several nitrofuran derivatives
possessing antibacterial activity. It is used exclusively as a urinary
antiseptic and is contained in the Sky Lab medical kits for that purpose.
A variety of enzymes are known to be inhibited by nitrofurans in vitro.
3
'
4
These enzymes are involved in redox reactions and include nitroreductase,
glutathione reductase, and aldehyde dehydrogenase. Inhibition of such
enzymic reactions is, in fact, thought to be intimately involved in the
mechanism of action of these compounds.5
PRECEDING PAGE BLANK NOT FILMED
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Three other drugs scheduled for use in the Sky Lab program,
when the need necessitates, are chloral hydrate, barbiturate, and fluraze-
pam. The purpose of the following work was to investigate the possible
interaction of these sedative drugs with nitrofurantoin, which might
result from its inhibition of a variety of enzymes. Specific studies
have compared the metabolic capabilities of microsomes from nitrofurantoin-
pretreated animals and controls, and the duration of sleep produced by
the sedative drugs in the two groups of animals.
In vitro metabolic rates for several substrates were studied
using liver microsomes from control rats and from rats chronically dosed
with nitrofurantoin. The substrates were as follows: hexobarbital, which
provides a measure of barbiturate oxidase activity; meperidine, which
provides a measure of microsomal N-demethylase; and p-nitrobenzoic acid,
which measures the enzyme nitroreductase. In addition to measuring gross
body and liver weights in the two groups of animals, cytochrome P-450
and b5 were determined in microsomal preparation of control and nitro-
furantoin-treated animals.
Sleeping times produced after i.p. dosing with chloral hydrate
and hexobarbital were determined in control and nitrofurantoin-pretreated
animals. Since flurazepam did not produce a "sleeping time" as it is
usually defined, the inclined screen test was used to evaluate the potential
interaction between nitrofurantoin and flurazepam.
3. Materials and Methods
Male Sprague-Dawley rats were premedicated with nitrofurantoin
(24 mg/kg, p.o.) three times daily for five days for a total daily dose
of 72 mg/kg. The drug was given as a suspension in saline with 1% Tween
80. Control animals received only the vehicle (0.5 ml/lO0 g rat) on the
same dose regimen as the treated animals. On the sixth day, the animals
were sacrificed by decapitation and exsanguinated. Livers were excised
from control and treated rats, immediately placed in cold 1.15% KC1,32
and kept on ice. Each liver was weighed and homogenized in 20 ml 1.15%
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KC1 and the homogenate spun at 9000 x g for 30 min. The supernatant
was poured through a double layer of gauze to remove floating lipids.
It was then centrifuged in a refrigerated Beckman Model L3-50 ultra-
centrifuge (head 30) for 1.25 hr at 100,000 x g. The supernatant was
decanted and the pellets representing the microsomal fraction were
resuspended in cold 0.05M phosphate buffer, pH 7.4.
A protein determination was carried out on each microsomal
preparation using the Folin Phenol procedure.3 3  Each preparation was
then diluted with buffer to 20 mg protein/ml for the hexobarbital
oxidase, N-demethylase, and nitroreductase experiments, or to 2 mg
protein/ml for measurement of cytochrome levels. Incubation mixtures
to be used for in vitro metabolism studies were prepared immediately.
Secobarbital is the barbiturate being carried and used on the
Sky Lab program. This barbiturate was not metabolized in vitro by rat
liver microsomes at a rate sufficient to permit reliable kinetic studies
(NASA Final Report, Contract No. 9-9806). Hexobarbital was known to be
34
rapidly metabolized by rat liver microsomes in vitro and was used in
place.of secobarbital as the substrate for the barbiturate oxidase experiments.
The kinetics of metabolism of hexobarbital was followed by
observing the rate of disappearance of substrate using the analytical
method of Brodie et aZ.3 5  Incubation mixtures were prepared fresh for
each experiment and contained 20 mg microsomal protein, 20 pmoles
nicotinamide (Mann Research Labs.), 20 pmoles glucose-6-phosphate (Sigma
Chemical Co.), 25 pmoles of magnesium chloride, 2.25 pmoles of NADP
(Sigma), 2 units of glucose-6-phosphate dihydrogenase (Sigma) and 0.2,
0.3, 0.5, or 1.0 pmole of hexobarbital per 6 ml. Each mixture (12 ml)
was dept at 0* on ice at all times prior to incubation. At zero time,
a 5-ml aliquot of the mixture was taken and placed in 30 ml of heptane
containing 1.5% of isoamyl alcohol with 5 ml of 0.05 molar phosphate
buffer, pH 5.3, and saturated with NaCl. After removal of the zero
time sample, the incubation mixture was placed in a 370C shaking water
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bath (New Brunswick Scientific Co., Model G-77) and incubated for 7 min.
All incubations were carried out in air using a shaking rate of 150
oscillations per min. After 7 min, another 5-ml aliquot of the incubation
mixture was taken and placed in the heptane/buffer mixture to stop the
reaction. All samples were extracted by shaking in a reciprocal shaking
apparatus for 30 min. After extraction, each tube was centrifuged at
700 x g for 10 min in an International Model PR-6000 centrifuge.
For the determination of the barbiturate, a 7-ml aliquot of
the upper organic phase was added to 3 ml of 0.8M phosphate buffer, pH 11,
and shaken for 10 min. Samples were centrifuged, the organic phase
aspirated, and the optical density of the aqueous phase read at 240 and
280 nm. Using the optical density difference at 240 and 280 nm, the
concentration of barbiturate was determined. The amount of hexobarbital
that was metabolized was calculated from the difference between this
value and that found for the zero time sample.
Meperidine rather than flurazepam itself, was used for probing
N-dealkylation in vitro since acetaldehyde - one product of N-de-ethylation
of flurazepam - is not so readily determined as formaldehyde.
The rate of formaldehyde production from meperidine was
determined using the Nash procedure.3 6  Incubation mixtures were prepared
as described for the hexobarbital oxidase, but with the addition of 15
moles of semicarbazide hydrochloride/ml of incubation mixture. This
traps the formaldehyde as its semicarbazone, preventing its further oxidation
to carbon dioxide. Drug levels were 1, 2, 10, and 20 pmoles of meperidine
per 6 ml of incubation mixture. The mixture was incubated under air at
370 C in the shaking water bath and at 7 min a 5-ml aliquot was taken.
This was immediately added to 2 ml of 10% ZnSO 4 (W/V using anhydrous
ZnSO 4 ) to stop the reaction. Each sample was agitated with a Vortex
mixer and after 5 min, again agitated. A saturated barium hydroxide
solution (4 ml) was added to each sample and the tube was agitated and
centrifuged at 15,000-17,000 rpm for 10 min. If the supernatant was
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cloudy, known amounts of the 10% ZnSO 4 solution or saturated barium
hydroxide solution were added until it became clear.
To a 5-ml aliquot of the clear.supernatant, 2 ml of freshly
36
prepared double-strength Nash reagent *was added and the mixture incubated
for 30 min at 600C. The yellow color which developed was quantitated by
reading optical density at 412 nm. The yellow color was caused by the
formation of 3,5-diacetyl pyridine from 2,3-butanedione and formaldehyde
in the presence of ammonium acetate in the Nash reagent.
Nitroreductase activity was determined by the method of Fouts
and Brodie37 as modified by Umar and Mitchard. The supernatant fraction
from the 100,000 x g spin was used instead of the isolated microsomes for
investigating nitroreductase activity. Nitroreductase appears to be a
soluble cytoplasmic enzyme and not microsomal, as it has been reported
that the ability to reduce p-nitrobenzoic acid is associated only with
4
the supernatant fraction. The incubation mixture used in these studies
had the following composition: 3.0 mole NADPH (Sigma Chemical Co.),
0.094 Imole riboflavin (Sigma), 4.5 pmole nicotinamide (Mann Research
Laboratories), and 17.6 pmole glucose-6-phosphate (Sigma) in 0.5 ml
phosphate buffer, pH 7.4, 2 ml liver supernatant, and 1 ml of either
10- 4 , 5 x 10 , 10- 3 , or 5 x 10-3M p-nitrobenzoic acid. Incubations were
carried out anaerobically at 370C as nitroreductase is inhibited by
oxygen. The rate of appearance of p-aminobenzoic acid was shown to be
linear with time for 90 min. At the end of 1 hr, 1 ml 5% trichloroacetic
acid solution was added to the samples to stop the reaction and precipitate
protein. The precipitate was removed by centrifugation and 3 ml aliquots
of the clear supernatant were removed for analysis.
The amount of p-aminobenzoic acid formed in 1 hr was determined
38
by the method of Bratton and Marshall. One ml of 0.1% sodium nitrite
was added to the 3 ml of clear supernatant and the samples vortexed.
After standing at room temperature for 3 min, 1 ml of 0.5% ammonium
sulfomate was added and the samples were again vortexed. One ml of 0.1%
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N(l-naphyl)ethylenediamine was added after 2 min, the samples vortexed
and, following a 3 min wait, the absorption determined at 550 nm.
Throughout the section dealing with metabolism in vitro, rates
will be expressed in terms of millimicromoles of substrate metabolized
(or millimicromoles of metabolite appearing)/mg microsomal protein/min.
These units are commonly used by other workers.39
40 Cytochrome b5 was determined by the method of Strittmatter 
and
Velick. Cytochrome P-450 was determined as described by Omura and
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Sato. An aliquot of the microsomal protein suspension was diluted with
0.05M phosphate buffer, pH 7.6 (EDTA 10-3M) to a concentration of 2 mg/ml.
Three ml of this dilution were aliquoted into two matched cuvettes.
A few milligrams of sodium hydrosulfite were added to the cell sample
and, after mixing the contents, the difference spectrum was recorded
(Figure 5). The sample cuvette was then placed in the reference beam
and the reference cuvette treated as follows: carbon monoxide was gently
bubbled through for approximately 20 sec, then a few milligrams of sodium
hydrosulfite were added, followed by carbon monoxide being bubbled through
for another 20 sec. This cuvette was then placed in the sample beam and
the difference spectrum recorded (Figure 6).
Cytochrome b5 levels are expressed as the optical density
difference between 427 nm and 407 nm/10 mg microsomal protein/3 ml.
Cytochrome P-450 levels are expressed as optical density differences
between 450 nm and 490 nm/10 mg microsomal protein/3 ml in this standard
procedure. This is adequate for the purposes of this study since we
are interested in comparing groups rather than absolute amounts of
cytochrome.
Pharmacological studies were set up to measure the effect of
chronic dosing with nitrofurantoin on chloral hydrate-induced sleeping
times. Preliminary studies established that a dose of 200 mg/kg i.p.
of chloral hydrate and 80 mg/kg i.p. of hexobarbital produced a convenient
length sleeping time in normal rats. Sleeping times were recorded
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Difference spectra of cytochrome b5
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Difference spectra of cytochrome P-450
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as the interval between loss and return of the righting reflex. The
criteria for the loss and return of the reflex were the inability and
ability, respectively, of the animal to right itself within 30 sec when
placed on its back.4 2
Since flurazepam did not appear to produce a "sleeping time"
as it is usually defined by the righting reflex, the inclined screen
test 4 3 was the method chosen to evaluate the potential interaction between
nitrofurantoin and flurazepam. Control animals were dosed with different
levels of flurazepam to establish an effective dose, defined as that dose
which produced a paralyzing effect severe enough to allow a rat to slide
off a 70* inclined screen within 1 min. At 100 mg/kg i.p., the length
of time between administration of flurazepam and the paralyzing effect
was approximately 10 min. It is this time which was used as a basis
of comparison between control and nitrofurantoin-treated animals.
4. Results and Discussion
(a) Microsomal Studies. Chronic dosing of rats with nitrofurantoin
produced no gross effects on total body weight, liver weight, or yield
of microsomal protein (Table 1). Cytochrome P-450 and b5 enzyme levels
were equivalent from control and nitrofurantoin-treated animals (Table 2).
The rate of hexobarbital metabolism has been shown to be linear
with time to 10 min and has good substrate dependence (Final Report to
NASA, October 31, 1970, Contract NAS 9-9806). The metabolic rates for
control and nitrofurantoin-treated animals are given in Table 3. The
rate data plotted in Lineweaver-Burk form are presented in Figure 7.
The modest trend towards an increase in hexobarbital metabolism is not
significant since animals in subsequent pharmacological studies were
not affected by pretreatment with nitrofurantoin.
The two major metabolic pathways for meperidine are N-demethyla-
tion and ester hydrolysis. Microsomal N-demethylase activity was studied
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TABLE 1
EFFECT OF CHRONIC TREATMENT WITH NITROFURANTOIN ON TOTAL BODY AND LIVER WEIGHT AND YIELD OF MICROSOMAL
PROTEIN
Body Weight (g)a Liver Weight (g) Ratio b No. of Microsomal yield Assayed for
Animals mg protein/g liver
Treated 146.0 ±7.0 7.5+0.7 0.051 4 19.3 Nitroreductase/cytochrome
Control 145.3 ±3.4 7.1±0.4 0.049 4 18.0 enzymes
Treated 161.8 +2.4 8.1±0.4 0.048 4 19.0 Nitroreductase/barbiturate
Control 161.0 16.5 8.1±1.4 0.051 4 18.6 oxidase
Treated 167.0±11.8 7.9+1 .1 0.047 4 18.8 N-demethylase/cytochrome
Control 168.5± 5.2 8.5±0.5 0.050 4 19.1 enzymes
Treated 168.5± 5.2 9.1±0.6 0.054 4 18.5 N-demethylase/barbiturate
Control 169.3± 7.6 7.9±0.6 0.047 4 17.9 oxidase
a Mean ±S.D.
b
Ratio of mean liver weight/mean body weight.
TABLE 2
EFFECT OF CHRONIC TREATMENT WITH NITROFURANTOIN ON RAT LIVER CYTOCHROMEa
No. of animals Cytochrome P-45d Cytochrome b5b
Treated 4 0.292±0.024 0.394±0.042
Control 4 0.263±0.060 0.423±0.077
Treated 4 0.287±0.036 0.381±0.053
Control 4 0.291±0.041 0.401±0.068
a Results from two experiments reported separately.Mean ±S.D.
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TABLE 3
MICROSOMAL HEXOBARBITAL OXIDASE ACTIVITY AFTER CHRONIC NITROFURANTOIN
PREMEDICATION
Substrate Rate
(micromoles/6 ml of incubation mixture) (mimoles hexobarbital metabolized/
mg protein/minute)a
EXPERIMENT 1
Control Treated
0.32 0.254±0.089 0.402±0.085
0.50 0.489±0.087 0.566±0.176
0.92 0.730±0.182 0.789±0.209
1.86 1.150±0.297 1.572±0.233
EXPERIMENT 2
0.32 0.216±0.078 0.350±0.072
0.50 0.426±0.073 0.484±0.149
0.92 0.625±0.156 0.679±0.183
1.86 0.976±0.248 1.342±0.213
Mean ±S.D. for 4 animals
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FIGURE 7
Lineweaver-Burk plot of hexobarbital oxidase activity in control and
nitrofurantoin-treated rats.
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by following the rate of appearance of formaldehyde. The rate of
formaldehyde production has been shown to be linear with time to about
10 min and has good substrate dependence (see ref. for hexobarbital).
The rate data obtained using liver microsomes from control and nitro-
furantoin-treated rats are given in Table 4. The rate data plotted in
Lineweaver-Burk form are presented in Figure 8. It is apparent that
there was no significant effect on N-demethylase due to chronic dosing
of rats with nitrofurantoin.
Furadantin and some related nitrofuran analogues, added
directly to guinea pig liver microsomal preparations, have been reported
to inhibit completely the nitroreductase reduction of p-nitrobenzoic
acid. To complete the metabolic profile of rats chronically dosed with
nitrofurantoin, nitroreductase was determined by using p-nitrobenzoic
acid as the substrate and following the rate of appearance of p-amino-
benzoic acid. Figure 9 depicts the linearity and substrate dependency
of the reaction. Metabolic rates are presented in Table 5. Lineweaver-
Burk graphs of the data are shown in Figure 10.
These studies, like the previous ones, demonstrated the absence
of drug effect of nitrofurantoin on the nitroreductase activity in
microsomal preparation from livers.
Each parameter - body and liver weights, microsomal protein
concentrations, liver cytochrome concentrations, hexobarbital oxidase
activity, N-demethylase activity, and nitroreductase activity - has been
examined in two separate experiments. Each experiment involved the
highest proposed dose level of nitrofurantoin (24 mg/kg t.i.d. or
72 mg/kg/day for 5 days). No significant effect was observed, except
possibly on hexobarbital oxidase. However, even this possibility was
not demonstrated at the pharmacological level.
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TABLE 4
METABOLIC RATES OF MEPERIDINE IN VITRO USING LIVER
MICROSOMES FROM CONTROL AND NITROFURANTOIN-TREATED RATS
Substrate Rate
Concentration (pM) (mpmoles H2CO/mg protein/min)a
Experiment 1
Control Treated
1 0.39 + 0.01 0.52 ± 0.12.
2 0.49 + 0.05 0.54 ± 0.12
10 0.61 + 0.06 0.61 ± 0.12
20 0.75 + 0.12 0.74 ± 0.18
Experiment 2
Control Treated
1 0.57 ± 0.08 0.52 ± 0.10
2 0.73 ± 0.07 0.61 ± 0.11
10 0.86 ± 0.09 0.78 ± 0.09
20 0.89 ± 0.10 0.75 ± 0.10
a Mean ±S.D. of 4 animals
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Lineweaver-Burk plot of N-demethylase activity in control and nitro-
furantoin-treated rats.
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FIGURE 9
Rate of production of p-aminobenzoic acid from p-nitrobenzoic acid at
several substrate concentrations.
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TABLE 5
MICROSOMAL NITROREDUCTASE ACTIVITY AFTER CHRONIC NITROFURANTOIN
PREMEDICATION
Substrate Rate
Concentration (Molar) (mpmoles p-aminobenzoic acid/mg protein/hr)a
Experiment 1
Control Treated
5 x 10- 3  5.33 ± 1.78 5.33 + 1.65
10 - 3  3.32 ± 0.81 2.90 + 0.46
5 x 10- 4  1.76 ± 0.41 2.01 + 0.31
10 0.77 ± 0.13 0.93 + 0.08
Experiment 2
5 x 10-3  3.75 ± 0.77 4.61 + 1.40
10 - 3  1.87 ± 0.27 1.83 ± 0.13
5 x 10-4  1.00 ± 0.07 0.93 ± 0.08
10 0.50 ± 0.13 0.59 ± 0.03
a Mean ±S.D. for 4 animals
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Lineweaver-Burk plot of nitroreducrase activity in control and nitro-
furantoin-treated rats.
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(b) Pharmacological Studies. It has been reported in a
rather obscure paper8 that nitrofurantoin (100 or 200 mg/kg) potentiates
the sleeping time produced by hexobarbital in the rat. The mechanism
of this potentiation is unknown, but it again seemed not unreasonable
that inhibition of oxidative metabolism of the barbiturate may be
involved. As the average daily oral dose of nitrofurantoin in humans
is 5-10 mg/kg, the dose of 100 or 200 mg/kg used in the above study
may be unrealistically high. Using dosage conversion factors suggested
by Freireich et aZ. 9 and recognizing their approximate nature, a dose
for the rat which is comparable to 5-10 mg/kg in the human, should be in
the range of 35-70 mg/kg. Freireich's conversion factors are used for
estimating dosage equivalency on the basis of mg/m2 of body surface area,
rather than body weight.
Pharmacological studies were set up to measure the effect of
chronic dosing with nitrofurantoin on hexobarbital-induced sleeping
times. Rats were previously dosed with nitrofurantoin (72 mg/kg) or
the control vehicle for 5 consecutive days. On the sixth day, all animals
were dosed with hexobarbital. Preliminary studies established that a
dose of 80 mg/kg i.p. of hexobarbital produced a convenient length
sleeping time in normal rats. The results, compiled from two separate
experiments, are reported in Table 6. It is readily apparent that nitro-
furantoin pretreatment did not have any effect on the duration of sleep
produced by hexobarbital. A similar conclusion is also reached when
chloral hydrate (200 mg/kg i.p.) was the sedative (Table 6).
The rationale for including flurazepam in these studies was
merely to complete this set of experiments with the third operational
sedative drug. The route of metabolism of nitrofurantoin is unknown
so that the possibility of chronic dosing with nitrofurantoin affecting
the way rats responded to flurazepam was speculative.
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TABLE 6
EFFECT OF CHRONIC DOSING WITH NITROFURANTOIN ON HEXOBARBITAL- AND CHLORAL HYDRATE-INDUCED SLEEPING
TIMES IN RATS
No. of Mean Body Weight Hexobarbital/Chloral Sleeping Times
Group Animals (g) ± S.D. Chronic Treatment Hydrate Dose (min S.D.)
1 15 165.5 ± 10.3 1% Tween 80/saline, 80 mg/kg i.p. hexo- 18.6 + 5.2
0.5 ml/100 g rat barbital, Day 6
p.o., t.i.d. for
5 days
2 20 159.9 ± 12.2 Nitrofurantoin in 1% 80 mg/kg i.p. hexo- 19.9 + 8.9
z- Tween 80/saline, 24 barbital, Day 6
n mg/kg p.o., t.i.d.
for 5 days
3 15 169.7 ± 16.1 1% Tween 80/saline, 200 mg/kg i.p. 17.8 + 9.0
0.5 ml/100 g rat chloral hydrate,
p.o., t.i.d. for Day 6
5 days
4 20 162.4 + 13.7 Nitrofurantoin in 200 mg/kg i.p. 15.6 + 5.6
1% Tween 80/saline, chloral hydrate,
24 mg/kg p.o., t.i.d. Day 6
for 5 days
-t
3"
As explained in the methods section, the inclined screen test
was chosen to evaluate the potential interaction between nitrofurantoin
and flurazepam since the latter drug did not appear to produce a
measurable sleeping time. Rats were predosed with either nitrofurantoin
or control vehicle as described above, and on Day 6, received 100 mg/kg
flurazepam i.p. The mean time in minutes between dosing with flurazepam
and the paralyzing effect which caused the animal to slide off the 700
inclined screen was essentially the same for control and nitrofurantoin-
treated animals, 10.89 ± 5.49 and 10.89 ± 4.88, respectively. Based on
our experience, we feel that the inclined screen test used to measure
the flurazepam interaction does not appear to be a very sensitive
mechanism for noting small differences between groups of animals. Since
there was no difference between the two groups, we must assume that
there was no significant potentiation or inhibition of flurazepam action
by nitrofurantoin. Any subtleties of drug interaction, however, would
not have been detected by this method.
The significance of this work has been defined as test results
that differ from control values by a "p" value of less than 0.05, as
measured by the "t" Test. In other words, the probability (p) that the
values obtained with treated animals and values obtained with control
animals are different by chance alone is less than 5%. Based on this
definition, neither the in vivo nor the in vitro experiments produced
any significant differences between control and nitrofurantoin-treated
animals. The only possible exception was the hexobarbital oxidase
experiments which did show an increase in the rate of hexobarbital
metabolized by microsomes from treated animals but significance at the
defined level was found only at the lowest (0.32 pmoles/6 ml incubation
mixture) substrate level. Complementary experiments measuring the
in vivo effect of nitrofurantoin on hexobarbital-induced "sleeping
times" did not indicate any differences between control and treated
animals.
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B. Studies of Potential Interactions of Enzyme Inducers with
Phenazopyridine.
1. Summary
Studies were carried out in several species to determine
whether induction of liver microsomal enzymes would increase the tendency
of phenazopyridine to produce methemoglobin in vivo. Animals were
premedicated with phenobarbital, a known inducer of azoreductase, and in
a separate experiment with flurazepam, before administration of phen-
azopyridine. Methemogl6bin production was determined in each animal
after receiving phenazopyridine. No evidence was found for increased
production of methemoglobin in the rat, dog, or rabbit that could be
attributed to increased amounts of microsomal enzymes.
2. Introduction
Phenazopyridine is an old drug developed originally as a urinary
antiseptic but used now principally as a urinary tract anesthetic, either
alone or in combination with sulfonamides. The clinical structure of
phenazopyridine is related to the aniline compounds whose most commonly
described toxic effect is methemoglobinemia. In fact, methemoglobinemia,
and more rarely, hemolytic anemia, has been reported to be produced by
15-17
this drug. Accidental overdoses with phenazopyridine have led to
production of large amounts of methemoglobin and cyanosisl 8 in humans,
while a dose of 200 mg/kg, admittedly quite high, produced anemia in
the dog.19 The large doses required to produce this effect suggests
that this is not a complication to be expected in the usual clinical
administration.
The metabolism of phenazopyridine has apparently never been
studied, but there is ample analogy for the suggestion that it will be
metabolized by azoreductase. While phenazopyridine apparently can, by
itself, produce methemoglobin in vitrol6 the products o'f reduction of
the azo linkage should be much more potent in producing methemoglobin.
47
Athur D Little lnc
Production of some methemoglobin by a drug is ordinarily not an important
clinical problem, but impairment of any of the oxygen transport capacity
of individuals subject to extreme physical exertion may be another matter.
Azoreductase is an inducible enzyme and our interest here is whether the
presence of enzyme inducers will tend to increase formation of methemo-
globin by phenazopyridine. As pointed out above, methemoglobin production
by this drug has only been reported with excessively large doses and
accidental overdoses. The standard dose used for our studies will be
roughly equivalent to the dose for man computed as mg/m 2 of body surface
area.
Two drugs, phenobarbital and flurazepam, were investigated as
to their ability to induce azoreductase and the subsequent effect of an
increased production of enzyme on the amount of methemoglobin produced
by phenazopyridine. These studies utilized several animal species.
3. Materials and Methods
Phenobarbital is already known to induce azoreductase in the
21
rat and other species including humans. Before beginning the drug
combination studies, the ability of phenobarbital to induce azoreductase
in the rat was re-demonstrated under our laboratory conditions.
Rats were dosed with phenobarbital (80 mg/kg, i.p.) for 3, 4,
or 5 consecutive days. Control animals received saline (0.5 ml/100 g
rat, i.p.) at the same time that the experimental group received
phenobarbital. The animals were sacrificed by decapitation and exsan-
guinated. The livers were excised immediately and placed in cold 1.15%
44
KC1. The method of Smith and VanLoom utilizing 1,2-dimethyl-4-
(p-carboxyphenylazo)-5-hydroxybenzene (CPA) as a substrate for measuring
azoreductase activity was chosen over the method of Fouts et al.2 2
which used Prontosil (4'-sulfamyl-2,4-diaminoazobenzene), as the latter
is not commercially available. p-Aminobenzoic acid is a product of CPA
cleavage and, therefore, the standards and procedures for the colorimetric
determination of nitroreductase can be utilized.
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Crude enzyme preparations were obtained by homogenizing the
livers at 40 C in 20 ml 1.15% KC1 and centrifuging at 9000 x g for 30 min.
The supernatant was poured through a double layer of gauze to remove
floating lipids. Incubation mixtures consisted of: 1.43 ml 0.1M sodium
phosphate buffer, pH 7.4; 0.5 ml of a mixture containing 25 pmoles glucose-
6-phosphate, 12.5 pmoles MgC12 , and 25 pmoles nicotinamide; 0.12 ml NADP;
0.2 ml buffer containing 1.2 enzyme units of yeast glucose-6-phosphate
dehydrogenase; and 0.25 ml 9000 x g supernatant fraction. Individual
incubation flasks were flushed with nitrogen for 5 min before the addition
of 0.2 ml CPA (0.01M solution in ethanol/0.5M Na2HP04, 1:1;V:V). Incuba-
tions were continued under nitrogen for 30 min in a 370C shaking water
bath (150 oscillations/min). The reaction was stopped by the addition
of 2.5 ml 10% trichloroacetic acid (TCA). The mixtures were then
centrifuged at 40C and 2.5 ml clear supernatant was removed for analysis.
0.5 ml of freshly prepared 0.1% (W/V) sodium nitrite was added to each
sample, followed after 5 min by 0.5 ml 0.5% (W/V) ammonium sulfonate.
Approximately 5 min later, 0.5 ml 0.1% (W/V) N-(l-naphthyl)ethylene-
diamine was added and the mixture allowed to react for 15 min. Solutions
were swirled rigorously after each addition. Absorbence was measured at
540 nm.
The amount of nonenzymic cleavage was determined by the simultaneous
incubation of the NADPH-generating system with CPA for the incubation
period. Aliquots of the 9000 x g supernatant fraction (0.25 ml) were
added after the addition of TCA and the samples were treated as above.
The amount of enzyme present was expressed as pg p-aminobenzoic acid/mg
protein/30 min incubation.
The experiment described above in detail for phenobarbital was
carried out with flurazepam. Rats were dosed i.p. consecutively for 3,
4, or 5 days with flurazepam at either 100 mg/kg or 200 mg/kg and the
livers were analyzed for flurazepam.
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Once the ability of phenobarbital to induce azoreductase had
been demonstrated in the rat, an experiment was run with a known methemo-
globin producer, aniline, as a check on the experimental design and
methods to be used in subsequent drug interaction studies with phenazo-
pyridine. Rats were predosed with phenobarbital (80 mg/kg i.p.) or
saline (0.5 ml/100 g rat) for 3 days. On day 4, half of the pheno-
barbital-treated rats and half of the control rats received aniline at
1 g/kg orally while the other half of the animals received a dose of
500 mg/kg p.o. Blood was analyzed at 30 min, 1, 3, 6, 12, and 24 hr
for MHb concentration.
The original procedure used to determine the level of methemo-
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globin (MHb) in blood was the method of Evelyn and Mallory. Fresh
whole blood (0.1 ml) was pipetted into 10 ml of M/60 phosphate buffer,
pH 6.6, and the optical density measured at 635 nm (A1). One drop of
neutralized sodium cyanide was then added to convert any methemoglobin
present to cyanmethemoglobin, and a second reading was taken at 635 nm
(A2). The optical density difference (A1-A2) should be proportional to
the concentration of methemoglobin in the original blood sample. Problems
were encountered with this method when blood samples contained little or no
methemoglobin. In this instance, the lysed cells caused light scattering
and thus interfered with the optical density measurement at 635 nm.
This problem was solved by centrifuging the samples before optical
density readings were taken.4 6 This eliminated the turbidity due to the
lysed cells and allowed for a more accurate determination. Standards
have been analyzed and have demonstrated the reliability of the procedure
(Figure 11).
4. Results and Discussion
(a) Induction of Azoreductase. Phenobarbital is already
known to induce azoreductase in the rat2 1 and other species including
humans. As seen in Table 7, azoreductase in rat liver was found to be
induced within three days of dosing with phenobarbital but was not
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FIGURE 11
Standard curve for methemoglobin determination
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TABLE 7
MEASUREMENT OF AZOREDUCTASE INDUCTION IN CONTROL AND PHENOBARBITAL-
TREATED RATS
Number of days ug p-aminobenzoic acid/mg protein/30 min incubation
of phenobarbital
pretreatment Phenobarbital-treated ratsa Control ratsa
3 days 0.72 ± 0.06 0.41 ± 0.05
3 days 0.77 ± 0.06 0.41 ± 0.07
4 days 0.86 ± 0.19 0.49 ± 0.09
5 days 0.94 ± 0.10 0.48 ± 0.08
Mean of 5 animals + S.D.
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significantly higher after 4 or 5 days of pretreatment. Changes in
other parameters, e.g., liver weight, protein concentration, were not
apparently affected by the phenobarbital treatment (Table 8).
Induction of drug-metabolizing enzymes by flurazepam has not
been reported, but flurazepam is still a relatively new drug. The closely
related drugs, diazepam and chlordiazepoxide, will induce microsomal
enzymes in the rat.23 The particular enzymes shown to be inducible were
an 0-demethylase (substrate = p-nitroanisole), an aryl hydroxylase
(substrate = aniline), and an N-demethylase (substrate = amidopyrine).
Table 9 shows that pretreatment of rats with flurazepam did not signifi-
cantly induce azoreductase concentrations. Although the amounts of azo-
reductase were slightly high in the flurazepam-treated animals, the
results did not show any significant difference between the two drug
levels and only slight differences in enzyme levels over control animals.
Changes in other parameters, e.g., liver weights, protein concentration,
were not apparently affected by the flurazepam treatment (Table 10).
Table 11 shows that flurazepam only slightly increases cytochrome P-450
concentrations and has no effect on cytochrome b5 levels.
(b) Methemoglobin Production by Phenazopyridine. Rats
normally have very low levels of methemoglobin in blood, 1.3 ± 0.3 mg/ml,
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as reported by Heubner et aZ. The combination study with aniline and
phenazopyridine showed both dose levels of aniline increased the amount
of MHb found in the blood, while phenobarbital-treated animals had
concentrations of MHb significantly greater than saline-treated rats
(Figures 12 and 13). Since phenobarbital can enhance methemoglobin
production by aniline, the metabolic activation of aniline must also be
enhanced by phenobarbital. The induction of both enzyme systems,
azoreductase and metabolic activation of aniline and-possibly 2,3,6-
triamino pyridine by phenobarbital have been demonstrated in the rat and,
thus, an interaction between phenobarbital and phenazopyridine seemed
plausible.
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TABLE 8
EFFECT OF PHENOBARBITAL PRETREATMENT ON LIVER WEIGHTS AND PROTEIN LEVELSa OF RATS
No. of days Mean body weight (g)b Liver weight (g)b Gm wt. liver wt./ Mg protein/g liverb
of pheno- 100 g body wt.
barbital Treated Control Treated Control Treated Control Treated Control
3 days 143.20± 6.16 160.20±7.80 9.48±0.52 7.64±0.78 6.62 4.77 4.41±0.21 4.25±0.22
3 days 120.30± 5.08 122.10±5.28 8.99±0.68 7.12±0.59 7.50 5.84 3.70±0.34 3.65±0.14
4 days 132.00±10.93 133.50±9.26 9.54±0.93 8.64±1.24 7.23 6.47 3.36±0.24 3.02±0.19
5 days 141.89±18.15 142.50±8.61 9.85±1.94 9.72±0.88 6.94 6.83 3.18±0.24 2.83±0.34
Protein determination carried out on 9000x g supernatant fraction.
Mean ±S.D. for 4 animals.
C:
TABLE 9
MEASUREMENT OF AZOREDUCTASE INDUCTION IN CONTROL AND FLURAZEPAM-TREATED RATS
Number of Days .g p-aminobenzoic acid/mg protein/30 min incubation
of Pretreatment Flurazepam-treated ratsa Control Ratsa
100 mg/kg 200 mg/kg
3 days 0.52 ± 0.07 0.55 ± 0.10 0.41 ± 0.05
4 days 0.53 ± 0.09 0.55 ± 0.18 0.49 ± 0.09
5 days 0.53 ± 0.11 0.63 ± 0.10 0.48 ± 0.08
Mean of 4 animals ±S.D.
ft
TABLE 10
EFFECT OF FLURAZEPAM TREATMENT IN RATS ON LIVER WEIGHTS AND PROTEIN LEVELS
Number of Days cMean Body Weight Mean Liver Weight Ratio   mg Protein/g Liver
of FluraepAm a b a b a b a bTreatment Dose I Dose II Dose I Dose II Dose I Dose II Dose I Dose II
3 145.0±5.2 135.8±7.4 6.92±0.59 7.19±0.36 0.048 0.053 22.4 27.3
4 145.0±8.1 133.0±5.4 7.07±0.82 6.99±1.00 0.049 0.050 23.2 22.3
5 146.8±3.9 145.5±4.5 7.00±0.65 7.37±0.72 0.048 0.048 25.6 26.0
Saline Dose II Saline Dose II Saline Dose II Saline Dose II
Salined vs.
Flurazepam 166.0±10.4 141.0±8.2 8.13±0.32 7.56±0.42 0.049 0.054 17.5 19.3
un for 5 days
Dose of flurazepam - 100 mg/kg i.p.
b
Dose of flurazepam - 200 mg/kg i.p.
c Ratio of mean liver weight/mean body weight
Control vehicle 
- 0.5 ml saline/100 g rat
>1
D"
TABLE 11
EFFECT OF CHRONIC DOSING WITH FLURAZEPAMa ON CYTOCHROME ENZYME LEVELS
IN RAT LIVER MICROSOMES
Cytochromeb Cytochromeb
P-450 b
Treated Control Treated Control
0.484 0.300 0.434 0.400
0.467 0.344 0.434 0.408
0.467 0.292 0.450 0.392
0.434 0.320 0.400 0.430
0.463±0.021c  0.314±0.023c  0.430±0.021l 0.408±0.016 c
a Rats dosed with flurazepam at 200 mg/kg i.p. for 5 days.
Control animals received comparable doses of saline i.p. for
5 days.
b Results expressed as O.D. difference/2 mg protein/10 ml.
C Mean ±S.D. .for 4 animals.
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FIGURE 12
Concentration of methemoglobin following a single dose of aniline
(500 mg/kg) in control and phenobarbital-treated rats.
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FIGURE 13
Concentration of methemoglobin following a single dose of aniline
(1 g/kg) in control and phenobarbital-treated rats.
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Since phenazopyridine is a drug that would normally be given
in multiple doses, over extended periods of time, an experiment was run
using repetitive doses of phenobarbital and phenazopyridine. The results
for this experimental design are presented in Table 12 and show that even
after 6 and 7 days of consecutive doses with phenobarbital and phenazo-
pyridine, the concentration of methemoglobin in the blood of treated and
control rats was not affected. The methemoglobin concentration approxi-
mated that reported by Heubner et a. 4 7 previously quoted as 1.3 ± 0.3 mg
methemoglobin/ml whole blood.
.A final experiment investigating the potential interaction of
phenobarbital and phenazopyridine in the rat was set up involving high
levels of phenazopyridine (500 mg/kg and 1 g/kg), doses equivalent to
the test experiment run with aniline. All the previous experiments had
been run with the dose of phenazopyridine set at 20 mg/kg, which is
equivalent, on a mg/m 2 basis, to the dose for man. Two experimental
designs were chosen: one group of animals received multiple doses of
phenobarbital followed by a single dose of phenazopyridine (i.e., like
the aniline experiment), while the other group received multiple doses
of both phenobarbital and phenazopyridine. Appropriate control animals
were run with each design.
The results from this experiment are presented in Tables 13
and 14. Table 13 reports the results of the single dose study and shows
that no differences could be detected between the various groups. In
these experiments, azoreductase had been induced in the phenobarbital-
treated rats.
The results from multiple dosing with phenazopyridine (Table 14)
indicate an increase in methemoglobin content in all phenazopyridine-
treated animals (Groups 6-9) vs. control animals (Group 10). At most
of the time periods, however, no differences could be seen between those
animals treated with phenobarbital or saline, or those animals that
received 1 g/kg or 500 mg/kg phenazopyridine. The possible exception
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TABLE 12
LEVELS OF METHEMOGLOBIN IN CONTROL AND PHENOBARBITAL-TREATED RATS FOLLOWING MULTIPLE DOSES OF PHENAZOPYRIDINE
Treatment Sample time Concentration of MHb mg/ml whole blood - mean±S.D.a(range)
(dose) (hr) Six daysb Seven daysb
Group 1
Phenobarbital (80 mg/kg i.p.) 0.5 3.6 ± 3.9 (8.3 - <1.0) <1.0
plus 1 1.5 ± 1.4 (2.7 - <1.0) 1.2 + 1.2 (2.7 - <1.0)
Phenazopyridine (20 mg/kg p.o.) 3 2.3 ± 0.5 (2.7 - 1.5) <1.0
6 <1.0 <1.0
24 <1.0 <1.0
Group 2
Phenobarbital (80 mg/kg i.p.) 0.5 2.1 ± 1.4 (3.5 - <1.0)
plus 1 1.0 ± 0.9 (2.0 - <1.0)
1% Tween 80/saline (0.5 ml/ 3 <1.0
100 g rat p.o.) 6 1.0 ± 0.9 (2.0 - <1.0)
24 <1.0
Group 3
Saline (0.5 ml/100 g rat i.p.) 0.5 2.0 ± 2.1 (4.2 - >1.0)
plus 1 <1.0
Phenazopyridine (20 mg/kg p.o.) 3 <1.0
6 <1.0
24 <1.0
CONTINUED . . .
5-
TABLE 12 (CONTINUED)
Treatment Sample time Concentration of MHb mg/ml whole blood - mean±S.D.a (range)
(dose) (hr) Six days SeVen days
Group 4
Saline (0.5 ml/100 g rat i.p.) 0.5 2.5 ± 2.6 (6.2 - >1.0)
plus 1 <1.0
1% Tween 80/saline (0.5 ml/ 3 <1.0
100 g rat p.o.) 6 2.5 ± 2.5 (5.5-- >1.0)
24 <1.0
Mean of 5 animals
b Animal received both drugs or saline for 6 or 7 consecutive days
-t5-
TABLE 13
LEVELS OF METHEMOGLOBINa IN CONTROL AND PHENOBARBITAL-TREATED RATS FOLLOWING A SINGLE DOSE OF PHENAZOPYRIDINE
(3 days Pb (3 days Pb (3 days Saline (3 days Saline (3 days Saline
Treatment + Phen. 1 glkg Phen. 500 mg/kg Phen.lg/kg Phen. 500 mg/kg 1% Tween 80/Saline)
Day 4) Day 4) Day 4) Day 4)
30 min
7.5 5.5 1.5 4.0 4.0
3.5 1.5 >0.5 >0.5 1.5
0.7(4.8±2.8)b  >0.5(2.9±3.1) 2.7(1.0±1.1) 2.7(2.0±1.6) 4.0(2.0±1.9)
5.5 7.0 0.7 2.7 0.7
7.0 0.7 >0.5 0.7 >0.5
S1 hour
6.7 2.0 2.0 2.0 >0.5
1.5 3.5 7.0 5.5 1.5
1.5(3.6±2.8) 1.5(1.9±1.0) 3.5(3.8±1.9) 4.0(2.7±2.1) 5.0(2.1±2.1)
6.7 0.7 4.0 2.0 3.5
1.5 2.0 2.7 >0.5 0.7
3 hours
4.0 4.0 2.7 15.0 4.0
0.7 2.0 >0.5 11.0 5.5
7.0(2.5±3.0) >0.5(2.5±1.7) >0.5(2.3±2.3) 7.0(8.4±5.5) 6.7(4.6±1.5)
>0.5 2.7 4.0 >0.5 2.7
0.7 4.0 5.0 9.0 4.0
CONTINUED .
TABLE 13
(3 days Pb (3 days Pb (3 days Saline (3 days Saline (3 days Saline
Treatment + Phen. 1 g/kg Phen. 500 mg/kg Phen. 1 g/kg Phen. 500 mg/kg 1% Tween 80/Saline
Day 4) Day 4) Day 4) Day 4)
6 hours
>0.5 7.0 >0.5 1.5 2.7
4.0 5.0 6.7 5.5 >0.5
5.0(3.3±2.1) 2.0(4.3±2.0) 4.0(4.2±3.0) 13.0(6.4±4.2) 3.5(3.6±3.3)
2.7 5.0 7.5 7.0 2.7
5.0 2.7 2.7 5.0 9.0
24 hours
9.0 7.5 5.0 7.0 0.7
3.5(5.6±3.1) 5.5(4.9±1.8) 5.0 7.0(2.1±2.8)
1.5 5.0 >0.5(6.0±4.8) 11.0(7.6±2.2) 0.7
6.7 2.7 11.5 7.5 >0.5
7.5 4.0 7.5 7.5 2.0
a Concentration of MHb expressed as mg/ml whole blood
Mean±S.D.
TABLE 14
LEVEL OF METHEMOGLOBINa IN CONTROL AND PHENOBARBITAL-TREATED RATS FOLLOWING MULTIPLE DOSES OF PHENAZOPYRIDINE
Group 6 Group 7 Group 8 Group 9 Group 10
(6 days Pb (6 days Pb (6 days Saline (6 days Saline (6 days Saline
Treatment + 3 days Phen. 3 days Phen. 3 days Phen. 3 days Phen. 3 days 1% Tween
1 g/kg) 500 mg/kg) 1 g/kg) 500 mg/kg) 80/Saline)
30 min
5.5 10.0 13.0 24.0 0.7
9.5 1.5 8.2 20.5 5.5(2.5±2.5)
1.5(5.6±3.9)b  11.0(8.2±4.1) 11.5(10.1±2.1) 4.0(14.4±8.2) >0.5
2.0 7.0 8.2 14.5 1.5
9.5 11.5 9.5 9.0 5.0
IL 1 hour
11.0 14.5 17.5 8.2 >0.5
7.5 4.0 8.2(9.0±5.7). 7.5(10.9±4.7) >0.5(0.5±1.2)
10.0(8.0±2.7) 11.0(9.4±6.4) 4.0 7.0 >0.5
4.0 15.0 11.5 17.0 >0.5
7.5 0.7 4.0 15.0 2.7
3 hours
7.5 0.7 >0.5 2.0 >0.5
>0.5 7.0 >0.5 10.0 1.5
5.5(3.7±3.2) >0.5(5.3±4.7) 8.2(3.0±3.7) 4.0(5.4±4.9) >0.5(0.3±0.7)
5.0 9.5 1.5 11.0 >0.5
0.7 9.5 5.5 >0.5 >0.5
CONTINUED . . .
TABLE 14 CONTINUED
Group 6 Group 7 Group 8 Group 9 Group 10
(6 days Pb (6 days Pb (6 days Saline (6 days Saline (6 days Saline
Treatment + 3 days Phen. 3 days Phen. 3 days Phen. 3 days Phen. 3 days 1% Tween
1 g/kg) 500 mg/kg) 1 g/kg) 500 mg/kg) 80/Saline)
6 hours
7.0 5.0 49 2.7 1.5
Dead 6.5 23 16.5 >0.5(1.0±0.9)
12.5(9.5±7.9) 0.7(5.1±2.6) 11.5(24.0±15.6) 1.5(9.8±7.4) 2.0
18.5 6.5 10.2 17.0 >0.5
>0.5 7.0 26.5 11.5 1.5
24 hours
32.5 7.0 7.5 4.2 >0.5
Dead 5.5 4.4 13.0 2.7(1.6 2.5)
19.0(22.7±8.6) 0.7(7.7±6.5) 15.0(8.7±6.1) 7.0(6.2±4.2) 5.5
Dead 18.5 15.0 2.0 >0.5
16.5 1.0 1.5 5.0 >0.5
a Concentration of MHb expressed as mg/ml whole blood
Mean ±S.D.
-4
is Group 8, where two out of five rats which were dosed with 1 g/kg
phenazopyridine were dead 24 hr after the last dosing. Methemoglobin
levels in the remaining three animals were significantly higher than
the other groups.
The pattern of methemoglobin production seen in Table 14 is
similar to that found by Herken48 in cats, following the administration
of 5 mg/kg nitrophenylhydroxylamine. There is an initial rise in the
methemoglobin content of the blood, a marked decrease at 3 hr, followed
by another rise at 6 hr. Herken referred to this increase/decrease/
increase of methemoglobin formation as the "two-phase" formation
which might be based upon the velocity of the reconversion of MHb to
hemoglobin.
Preliminary experiments in our laboratory confirmed the fact
that rabbits are poor experimental animals to use when investigating
methemoglobin formation. The rabbit normally has very little methemoglobin
present in its blood (0.4 mg/ml) as reported by Heubner et al. 4 7 An
initial experiment investigating the potential interaction of multiple
doses of phenobarbital and phenazopyridine in rabbits was set up along
the lines of the rat experiments described above. Blood samples were
analyzed for MHb and no differences were found between control and treated
animals. Although the method of Evelyn and Mallory4 5 is not sensitive
enough to determine accurately MHb in the small concentrations normally
present in rabbit blood, it would detect any prominent increases.
An experiment was run giving large doses of aniline to control
and phenobarbital-treated animals. Rabbits were predosed for 3 days
with either 50 mg/kg, i.p. phenobarbital or a comparable amount of the
control vehicle, saline. Although the level of MHb in the rabbit's
blood increased, the amount found was still very low when compared to
the results of the rat experiment with aniline.
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Different species of animals have shown.varying susceptibilities
to MHb formation by a particular compound. Using as a criterion of
sensitivity the reciprocal of the dose required to produce a stated
concentration of methemoglobin, Lester 49 found that the cat was the most
sensitive species. If this species is listed as 100, the sensitivities
of the other species tested are as follows for the drug, acetanilid:
man, 56; dog, 29; rat, 5; rabbit, 0; monkey, 0. Cats are an extremely
difficult species to work with and healthy cats are not easy to procure
for experimental purposes.
As the rabbit was unacceptable, we investigated the possibility
of using the dog as the second species for this work. A single experi-
ment run with aniline at 200 mg/kg, p.o., without predosing with pheno-
barbital was run to test the ease with which this species produces MHb.
Figure 14 shows the rate of methemoglobin production over the 24-hr
sampling period. The dose of aniline was equivalent on a mg/m2 basis
to the dose given to rats but the amount of MHb produced was greater in
the dog.
Methemoglobin formation was then investigated in dogs pretreated
with phenobarbital and dosed with phenazopyridine. Two dogs received
phenobarbital at 50 mg/kg, i.p., and two received a comparable volume of
saline. Four hours later, all four dogs received an oral dose of phen-
anopyridine (50 mg/kg). Blood samples were tested for MHb content at
30 min, 1, 3, and 6 hr after the animals received phenazopyridine. This
schedule of dosing and sampling was repeated in the same four dogs for
a total of four days. The results, although somewhat erratic, indicate
a trend towards increased production of MHb following multiple dosing
with phenazopyridine. Phenobarbital, however, did not appear to potentiate
this effect.
Flurazepam was the second drug investigated for possible
potentiation of methemoglobin production by phenazopyridine. From the
above results involving phenobarbital and phenazopyridine, it appeared
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FIGURE 14
Level of MHb found in the blood of a dog following a single dose
(200 mg/kg) of aniline.
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that even if flurazepam did induce production of azoreductase, the
interaction between flurazepam and phenazopyridine in all likelihood
would not increase the production of MHb. This supposition was further
supported by the fact that flurazepam did not significantly induce
azoreductase and did not affect the cytochrome concentrations. Nevertheless,
several experiments were carried out in rats.
Rats received both drugs for 6 or 7 days and, as seen in Table
15, no significant differences in MHb concentration were noted among any
of the four groups of treated animals. A final experiment involving
high levels of phenazopyridine (500 mg/kg and 1 g/kg) was set up along the
lines described in the section on phenobarbital.
The results of this latter experimental design are presented
in Tables 16 and 17. Table 16 shows that a single dose of phenazopyridine
had no effect on methemoglobin concentrations, with the possible excep-
tion at 24 hr after dosing which does show a slight increase in methemo-
globin in the plasma of phenazopyridine-treated rats.
The results from multiple dosing with phenazopyridine and
flurazepam (Table 17) indicate an increase in methemoglobin content in
phenazopyridine-treated animals (Groups 6-9) over control animals (Group
10). No significant differences were noted between the two dose levels
of phenazopyridine or between flurazepam-treated animals over saline-
dosed animals. One interesting point is that three out of five animals
which received flurazepam and the highest dose of phenazopyridine were
found dead at 24 hr. This is similar to the results with phenobarbital.
However, methemoglobin levels in the two remaining animals were not
greatly increased over the other groups. The increase/decrease/increase
pattern of MHb production noted in the phenobarbital experiment was
seen in this experiment but at a much lower level.
Rats pretreated with either phenobarbital or flurazepam
followed by phenazopyridine given as a single dose or a series of daily
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TABLE 15
LEVELS OF METHEMOGLOBIN IN CONTROL AND FLURAZEPAM-TREATED RATS FOLLOWING MULTIPLE DOSES OF PHENAZOPYRIDINE
Treatment Sample time Concentration of MHb mg/ml whole blood - mean ±S.D.a (range)
(dose) (hr) Six daysb  Seven daysb
Flurazepam (200 mg/kg i.p.) 0.5 3.9 ± 2.4 (7.0 - 1.5) 1.9 ± 2.4 (5.0 - <0.5)
plus 1 3.2 ± 1.1 (4.2 - 2.0) 0.8 ± 0.9 (1.5 - <0.5)
Phenazopyridine (20 mg/kg p.o.) 3 1.2 ± 0.7 (2.0 - 0.7) 6.2 ± 7.4 (17.0- 0.7)
6 1.5 ± 0.9 (2.7 - 0.7) 5.5 ± 4.4 (9.5 - 0.7)
24 1.2 ± 0.6 (1.5 - <0.5) 1.8 ± 0.3 (2.0 - 1.5)
Group 2
Flurazepam (200 mg/kg i.p.) 0.5 2.0 ± 1.3 (4.2 - 0.7)
plus 1 2.1 ± 0.8 (3.5 - 1.5)
1% Tween 80/saline (0.5 ml/100 3 0.7 ± 1.6 (3.5 - <0.5)
100 g rat p.o.) 6 1.1 ± 0.6 (2.0 - 0.7)
24 2.1 ± 1.9 (5.5 - 0.7)
Group 3
Saline (0.5 ml/100 g rat i.p.) 0.5 1.7 ± 1.1 (2.7 - 1.5) 1.1 ± 1.6 (3.5 - <0.5)
plus 1 1.0 + 0.7 (1.5 - <0.5) 1.0 ± 1.1 (2.7 - <0.5)
Phenazopyridine (20 mg/kg p.o.) 3 0.6 ± 0.6 (1.5 - <0.5) 4.5 ± 3.4 (9.5 - <0.5)
6 0.3 ± 0.4 (0.7 - <0.5) 2.2 ± 3.0 (7.0 - <0.5)
24 0.7 ± 0.6 (1.5 - <0.5) 1.1 ± 1.0 (2.7 - 0.7)
CONTINUED
TABLE 15 (CONTINUED)
Treatment Sample time Concentration of MHb mg/ml whole blood - meanS.D.a (range
(dose) (hr) Six daysb Seven daysb
Group 4
Saline (0.5 ml/100 g rat i.p.) 0.5 1.7 ± 1.7 (4.2 - <0.5)
plus 1 2.7 ± 1.4 (5.0 - 1.5)
1% Tween 80/saline (0.5 ml/ 3 2.3 ± 3.0 (7.5 - <0.5)
100 g rat p.o.) 6 4.8 ± 3.7 (8.2 - 0.7)
24 1.3 ± 0.4 (1.5 - 0.7)
Mean of 5 animals
b
Animal received both drugs or saline for 6 or 7 consecutive days
-4
TABLE 16
LEVELS OF METHEMOGLOBINa IN CONTROL AND FLURAZEPAM-TREATED RATS FOLLOWING A SINGLE DOSE OF PHENAZOPYRIDINE
Group 1 Group 2 Group 3 Group 4 Group 5
(3 days Flur. (3 days Flur. (3 days Saline (3 days Saline (3 days Saline
Treatment + Phen. 1 g/kg Phen. 500 mg/kg Phen. 1 g/kg Phen. 500 mg/kg 1% Tween 80/Saline
Day 4) Day 4) Day 4) Day 4)
30 min
7.0 0.7 1.5 4.0 4.0
6.7 5.5 >0.5 >0.5 1.5
4.0(5.1±1.6)b  3.5(3.3±2.2) 2.7(1.0±1.1) 2.7(2.0±1.6) 4.0(2.0±1.9)
4.0 1.5 0.7 2.7 0.7
4.0 5.5 >0.5 0.7 >0.5
1 hour
3.5 1.5 2.0 2.0 >0.5
7.0 2.7 7.0 5.5 1.5
3.5(3.8±2.6) 3.5(2.7±1.0) 3.5(3.8±1.9) 4.0(2.7±2.1) 5.0(2.1±2.1)
>0.5 2.0 4.0 2.0 3.5
5.0 4.0 2.7 >0.5 0.7
3 hours
6.7 >0.5 2.7 15.0 4.0
3.5 2.7 >0.5 11.0 5.5
2.7(4.5±2.2) >0.5(2.4±4.1) >0.5(2.3±2.3) 7.0(8.4±5.5) 6.7(4.6±1.5)
7.0 >0.5 4.0 >0.5 2.7
2.7 9.5 5.0 9.0 4.0
SCONTINUED. . .
,C
TABLE 16 CONTINUED
Group 1 Group 2 Group 3 Group 4 Group 5
(3 days Flur. (3 days Flur. (3 days Saline (3 days Saline (3 days Saline
Treatment + Phen. 1 g/kg Phen. 500 mg/kg Phen. 1 g/kg Phen. 500 mg/kg 1% Tween 80/
Day 4) Day 4) Day 4) Day 4) Saline)
6 hours
6.7 2.0 >0.5 1.5 2.7
5.5 4.0 6.7 5.5 >0.5
1.5(5.8±4.3) 10.0(4.3±3.8) 4.0(4.2±3.0) 13.0(6.4±4.2) 3.5(3.6±3.3)
12.5 5.5 7.5 7.0 2.7
2.7 >0.5 2.7 5.0 9.0
24 hours
7.0 10.0 5.0 7.0 0.7
8.2 9.5 5.0 7.0(2.1 2.8)
11.0(10.7±3.2) 5.5(8.0±3.1) >0.5(6.0±4.8) 11.0(7.6±2.2) 0.7
12.5 11.0 11.5 7.5 >0.5
15.0 4.0 7.5 7.5 2.0
a Concentration of MHb expressed as mg/ml whole blood
Mean ±S.D.
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TABLE 17
LEVELS OF METHEMOGLOBINa IN CONTROL AND FLURAZEPAM-TREATED RATS FOLLOWING MULTIPLE DOSES OF PHENAZOPYRIDINE
Group 6 Group 7 Group 8 Group 9 Group 10
(6 days Flur. (6 days Flur. (6 days Saline (6 days Saline (6 days Saline
Treatment + 3 days Phen. 3 days Phen. 3 days Phen. 3 days Phen. 3 days 1% Tween
1 g/kg) 500 mg/kg) 1 g/kg) 500 mg/kg) 80/Saline
30 min
9.0 8.2 13.0 24.0 0.7
9.0 19.0 8.2 20.5 5.5(2.5±2.5)
10.0(9.7±2.4)b  7.0(9.9±6.2) 11.5(10.1±2.1) 4.0(14.4±8.2) >0.5
13.5 2.7 8.2 14.5 1.5
7.0 12.5 9.5 9.0 5.0
-U I1 hour
11.5 11.0 17.5 8.2 >0.5
(10.4±1.9) 19.5(11.4±5.6) 8.2(9.0±5.7) 7.5(10.9±4.7) >0.5(0.5±1.2)
12.5 13.0 4.0 7.0 >0.5
8.2 4.0 11.5 17.0 >0.5
9.5 9.5 4.0 15.0 2.7
3 hours
>0.5 7.0 >0.5 2.0 >0.5
7.5 13.5 >0.5 10.0 1.5
7.0(4.5±4.2) 1.5(5.2±5.1) 8.2(3.0±3.7) 4.0(5.4±4.9) >0.5(0.3±0.7)
> 8.2 1.5 1.5 11.0 >0.5
>0.5 2.7 5.5 >0.5 >0.5
IJ CONTINUED . . .
TABLE 17 CONTINUED
Group 6 Group 7 Group 8 Group 9 Group 10
(6 days Flur. (6 days Flur. (6 days Saline (6 days Saline (6 days Saline
Treatment + 3 days Phen. 3 days Phen. 3 days Phen. 3 days Phen. 3 days 1% Tween
1 g/kg) 500 mg/kg) 1 g/kg) 500 mg/kg) 80/Saline)
6 hours
- 8.2 49 2.7 1.5
15.5 19.0 23 16.5 >0.5(1.0±0.9)
11.0(10.9±3.4) 6.5(8.6±6.2) 11.5(24.0±15.6) 1.5(9.8±7.4) 2.0
8.2 6.5 10.2 17.0 >0.5
9.0 6.5 26.5 11.5 1.5
24 hours
9.0 1.5 7.5 4.2 >0.5
Dead 5.5 4.4 13.0 2.7(1,6±2.5)
Dead(8.4±0.8) 0.7(4.4±3.1) 15.0(8.7±6.1) 7.0(6.2±4.2) 5.5
Dead 7.0 15.0 2.0 >0.5
7.8 7.5 1.5 5.0 >0.5
a Concentration of MHb expressed as mg/ml whole blood
Mean ±S.D.
doses did not greatly affect the level of methemoglobin found in the
blood. Control rats dosed with a known methemoglobin producer, aniline,
showed increased levels of MHb over normal animals, while those animals
pretreated with phenobarbital showed an even greater level of MHb in the
blood. This experiment clearly demonstrated the soundness of the
experimental design and adequateness of the methods employed. This fact
suggests that the potential interaction of phenobarbital and flurazepam
with phenazopyridine is not affecting methemoglobin production.
Experiments involving high doses of phenazopyridine suggest
that it is not the interaction with enzyme inducers that is important
but the dose of phenazopyridine itself. Production of methemoglobin
by phenazopyridine has been reported in the dog and in humans but only
in overdose situations. Increased levels of methemoglobin were found in
the rat after multiple doses of 1 g/kg and 500 mg/kg phenazopyridine in
control-, phenobarbital-, and flurazepam-treated rats. The trend toward
increased levels of MHb was also noted in the dog experiment following
50 mg/kg phenazopyridine. The chance that phenobarbital and flurazepam
are reacting in some way with phenazopyridine is still a possibility and
is suggested by the fact that phenobarbital- and flurazepam-treated
animals died if they received high levels of phenazopyridine, whereas
control animals did not.
C. Studies on the Effects of Diphenoxylate on the Bioavailability
of Nitrofurantoin
1. Summary
Experiments were conducted in the dog and in man to determine
whether premedication with diphenoxylate would result in altered bio-
availability of Furadantin "or Macrodantin . The rate of drug excretion
in the urine was determined and a plot of percent drug absorbed vs. time
was constructed for each dosage form, with and without diphenoxylate
pretreatment. Drug in the urine was determined by both a chemical and
microbiological method.
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In the dog, two doses of diphenoxylate were studied with each
dog serving as its own pre-diphenoxylate control. Diphenoxylate was found
to alter substantially the excretion pattern of both forms of nitro-
furantoin, generally increasing total absorption.
On the basis of the work originally done in dogs, the present
contract was extended to include similar nitrofurantoin/diphenoxylate studies
in man. Six subjects received both dosage forms of nitrofurantoin alone
and in combination with diphenoxylate. The results of these studies are
inconclusive. The mechanism of action and an explanation of the interaction
between diphenoxylate and nitrofurantoin still remains unclear. In man,
the interaction does not appear to be significant, affecting only two
subjects out of six and with only one dose formulation (Furadantinq .
2. Introduction
Diphenoxylate is considered to be a drug of choice for the
management of diarrhea50and has been used by astronauts for control of
the bowel. It is clinically related to meperidine. A common side-
effect of morphine and, less so, meperidine, is constipation.51 With
diphenoxylate, action on intestinal motility is exaggerated while
control effects are minimal.
Quantitative understanding of the process of drug absorption
has not been achieved but several factors are known to be involved.
These include the rate of dissolution of the dosage form, the particle
size of the drug, pH of the intestinal content, and the presence of
parasympothetic blocking drugs and other drugs which may decrease
intestinal motility.
Nitrofurantoin is marketed in two solid dosage forms, micro-
crystalline in a tablet (Furadantin Eaton Laboratories), and macro-
crystalline in a capsule (Macrodantin®, Eaton Laboratories). Oral
absorption of these dosage forms have been studied by following urinary30
excretion of drug in the dog although detailed kinetics were not
presented. It was established that the rate of absorption of these two
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crystalline forms of nitrofurantoin is different, the macrocrystalline
form being more slowly absorbed. It has also been established30 that
with the macrocrystalline dosage form, the amount of antibiotic excreted
in urine is less than that found with the microcrystalline form during
the first 24 hr after the first dose. It was noted, however, that urinary
antibiotics exceeded minimum effective antibacterial levels with both
dosage forms.
The following work was done to investigate the possibility
that metabolism by intestinal micro-organisms and/or increased residence
time of the drug in the gut may play a role in determining how much
parent drug is ultimately absorbed. It should be noted that drug meta-
bolism by intestinal micro-organisms can account for a wide variety of
transformation.52 The overall metabolic profile of a drug may be changed
by metabolism in the gut which, in turn, may be altered by increasing
residence time in the gut.
Studies to determine the effect of diphenoxylate on the bio-
availability of nitrofurantoin have been carried out in dog and man.
In view of the purpose of the study, the commercial dosage forms of
Furadantin 0 and Macrodantin )were used, rather than bulk drug. These
studies were done using four female beagle dogs and six male subjects.
The rate of absorption of antibiotic and total antibiotic absorbed was
compared in each group and with each dosage form.
3. Materials and Methods
Control experiments determining the rate of 14C-inulin
clearance were run on each dog as a check on kidney function before the
dog was used for experimentation. 14C-inulin (5 mg/ml in 0.9% NaCl,
specific activity 4 mCi/mg) was infused into the right paw at approxi-
mately 1 ml/min. Blood samples were collected at 15, 30, 60, 90, 120
min and hourly thereafter for 8 hr. Each dog was catheterized and urine
was collected hourly during the inulin infusion.
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One hour after the'start of the inulin each dog was dosed
orally with either 100 mg of Furadantin or, in a separate experiment,
100 mg of Macrodantin®. The level of antibiotic in the urine was
measured in samples collected hourly to establish control levels for
both dosage forms in each dog. 14C-inulin clearance studies were also
run on each dog at the end of the study to make sure kidney functioning
had remained satisfactory throughout the series of experiments.
Nitrofurantoin in urine was analyzed using the chemical method
of Conklin and Hollifield53 and also by a modified microbiological
method of Jones et al. 5 4 In the Conklin and Hollifield procedure, drug
is extracted from urine with nitromethane, alkaline reagent is added
to produce a visible color and the concentration of the drug determined
by spectrophotometry. The method has a sensitivity of 10 ug/ml and a
standard curve that is linear to 100 pg/ml (Figure 15).
One ml urine plus 4 ml 0.lN HC1 was extracted with 10 ml
nitromethane by mixing for 2 min and the biphase was centrifuged for
10 min. An aliquot (4 ml) of the nitromethane layer was removed to a
clean test tube and 0.5 ml of 0.04M Hyamine solution (Packard) was added.
Each sample was mixed well and allowed to stand at least 1 min before
reading the optical density on a Zeiss spectrophotometer at 400 nm. Pure
nitromethane was used to set the instrument to zero absorbence. Samples
were read within 30 min after the addition of the Hyamine solution.
Urine samples were also assayed for growth inhibitory activity
against Escherichia coZi by a modified version of the tube method of
Jones et al.54
Stock cultures and assays were grown in nutrient broth (Difco)
with pH adjusted to 5.5 and incubation at 370C. Incubation was for
16-18 hr and growth was measured nephelometrically at 550 nm in a Lumetron
colorimeter.
80
Arthur D Little Inc
.75
.70
. 65
.60
. 55
.50
.45
.40 -
I.35
.30-
. 25
.20 -
. 15 -
.10
.05 -
5 10 30 60 100
pgtml
FIGURE 15
Standard curve of nitrofurantoin in urine
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For each assay, a dose-response assay to nitrofurantoin (at
0, 1, 2, 4, and 8 ug/ml) was determined in 5 ml of culture median which
contained 0, 0.25, 0.5, or 1 ml of zero time urine from one of the.
test dogs. Each test urine sample was assayed at 0.25, 0.5, and 1 ml
for 5 ml culture.
Most control urines showed progressively greater inhibition
("protection") of nitrofurantoin activity as the volume was increased and
there were occasionally indications of similar effects in the test
urines. For this reason, the nitrofurantoin equivalent for each test
volume of any given sample was calculated from the dose-response curve
for the same control urine volume. The final nitrofurantoin value for
a sample was calculated from the average of all the test volumes showing
meaningful inhibition. Most values in the final results were thus based
on 2 or 3 points except where low activity produced inhibition only in
the 1 ml assay tube.
Drug equivalents (pg/ml) as calculated by this method compare
with values obtained by analyzing the urine according to the clinical
method of Conklin and Hollifield. The latter method is reported as55
specific for the parent drug. As there has been some speculation: that
the metabolites of the nitrofurans, presumably reduced compounds, may be
more active antibiotics than the parent drug, it was hoped that the
microbiological method would pick up other biologically active forms of
the drug. No other active species were found as the level of antibiotic
determined by both methods was similar. This being the case, the results
from only one method, the chemical method, are presented.
In the dog studies, the effect of two dose levels of
diphenoxylate (2.5 mg/kg and 0.5 mg/kg) on the bioavailability of both
the macrocrystalline (Macrodantin) and the microcrystalline (Furadantin
dose forms of nitrofurantoin were investigated. The animals were dosed
orally with diphenoxylate 18 hr before receiving either Macrodantin®
or Furadantin p.o. To assure accurately timed urine collections,
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each dog was catheterized during the first 6 hr after receiving the
nitrofurantoin. A slow i.v. infusion (1 ml/min) of physiological
saline was given during the period to hydrate the animal and insure
a good flow of urine. The animals were fasted at least 4 hr prior to
dosing with diphenoxylate and food was withheld until the catheter was
removed 6 hr following dosing with either dose form of nitrofurantoin.
Water was supplied ad Zibitwn.
The clinical study in man was carried out by Medical and
Technical Research Associates, Inc., Needham, Massachusetts (FDA
approved, registered as IND 9806). Six subjects were used in these
studies and all received both dosage forms of nitrofurantoin (Macrodantin
and FuradantinR alone and in combination with diphenoxylate.
Subjects were selected who were without a history of significant
past illness and were found to have a normal medical examination immediate-
ly prior to initiation of the study.
Subjects selected for the study were between twenty-one and
forty years of age and weighed between 135 and 185 pounds. Laboratory
safety tests were undertaken prior to the study and consisted of
hemoglobin, hemaocrit, WBC with differential, glucose-6-dehydrogenase,
and an SMA 12/60 series of clinical tests. All laboratory parameters
were found to be normal before the subjects were admitted to the study.
Subjects were particularly screened and excluded if found to possess:
(1) Sensitivity to nitrofurantoin or related drugs
(2) Sensitivity to diphenoxylate or related drugs
(3) Any history of gastrointestinal complaints
(4) Sensitivity to atropine or atropic type drugs
(5) Impaired renal or hepatic function
(6) Abnormal glucose-6-phosphate dehydrogenase.
All volunteers were off any type of medication for two weeks prior to
the study and throughout the duration of the study. The schedule is
outlined in Table 18.
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TABLE 18
THE SEQUENCE OF ADMINISTERING DIPHENOXYLATE AND NITROFURANTOIN IN SIX
HUMAN SUBJECTS
Weeks of Study: 1 2 3 4
Drug administered: SUBJECT NUMBER
Macrodantin i1, 2, 3 4, 5, 6
Furadantin 4, 5, 6 1, 2, 3
Diphenoxylat plus
Macrodantint i1, 2, 3 4, 5, 6
Diphenoxyl e plus
Furadantini 4, 5, 6 1, 2, 3
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A 15-mg dose of diphenoxylate (two 2.5-mg tablets administered
three times daily) was given for three consecutive days prior to dosing
with nitrofurantoin to allow for a buildup of drug and metabolites in
the enterohepatic pool. This expectation was based on the pharmacokinetics
24,25
of diphenoxylate in man. It was presumed that the plasma levels
of diphenoxylate in man after three consecutive doses of 15 mg would
approximate those obtained with the smaller dose (0.5 mg/kg) used in the
dog study. The nitrofurantoin (200 mg) was given orally approximately
24 hr after the last dose of diphenoxylate. This dose appears appropriate
based on the pharmacokinetics of nitrofurantoin in man.56 The subjects
were given water prior to and for the first 6 hr after administering
the nitrofurantoin. Urine was collected at 2, 4, 6, 8, 12, and 24 hr
after the nitrofurantoin dosing. The subjects were fasted, except for
water, from the previous evening until the noon meal.
4. Results and Discussion.
(a) Studies in Dogs. Results from control experiments utilizing
both dosage forms of nitrofurantoin, Furadantintablets and Macrodantin®
capsules, in all the dogs are illustrated in Figures 16 and 17. Using
the clinical method of assay for nitrofurantoin, 26-45% of the oral dose
of Furadantin (Figure 16) was excreted in the first 12 hr, compared to
10-16% of the oral dose of Macrodantin (Figure 17) excreted over the
same period. As seen in Figures 18, 19, and 20, dogs 100, 101, and 102
exhibited similar excretion patterns; the macrocrystalline dosage
(Macrodantin ) appeared to be more slowly absorbed than the micro-
crystalline form (Furadantin®) and the extent of absorption of the
macrocrystalline form is less than the microcrystalline, as indicated by
a smaller amount excreted during the 48-hr collection period. These
results agree favorably with the work of Conklin et al.30 They observed
differences in urinary drug recoveries and in urinary drug excretion
patterns between the two dosage forms suggesting a slower rate of
absorption and a lower amount of antibiotic absorbed for the macrocrystals
as opposed to the microcrystals. Dog 103, on the other hand, appeared
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FIGURE 16
Cumulative excretion of Macrodantin in the urine of all the dogs.
Chemical method used to analyze urine.
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FIGURE 17
Cumulative excretion of Furadantin% in the urine of all the dogs.
Chemical mehtod used to analyze urine.
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FIGURE 18
Cumulative excretion of Macrodantin and Furadantin in the urine of
Dog 100. Chemical method used to analyze urine.
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FIGURE 19
Cumulative excretion of Macrodantin and Furadantin in the urine of
Dog 101. Chemical method used to analyze urine.
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FIGURE 20
Cumulative excretion of Macrodantin and Furadantin in the urine of
Dog 102. Chemical method used to analyze urine.
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to handle both dosage forms similarly (Figure 21). The total amount
of drug excreted (26-27%) and the pattern of excretion were similar for
each dose form.
Results from the combination studies involving two dose levels
of diphenoxylate (0.5 and 2.5 mg/kg) and both dosage forms of nitrofurantoin
are presented in Figures 22-29. With two exceptions, which will be noted
below in detail, diphenoxylate appeared to enhance the absorption of both
forms-of nitrofurantoin. There did not, however, appear to be a clear
relationship between the amount of diphenoxylate given and the increased
amount of nitrofurantoin absorbed, the data varying with each dog. In
some animals, the lower dose of diphenoxylate (0.5 mg/kg) yielded a
greater percentage of drug absorbed than the higher dose of 2.5 mg/kg.
Two dogs with different dosage forms showed a reversal of
the general trend toward increased absorption. At both diphenoxylate
levels, Dog 102 absorbed less Macrodantin and Dog 100 absorbed less
Furadantin Bthan they absorbed in control experiments without diphen-
oxylate (Figures 24 and 26).
The experiments investigating the interaction of diphenoxylate
and Macrodantin are illustrated in Figures 22-25. Dog 100 (Figure 23)
showed increased drug absorption following the higher dose of diphenoxylate
(2.5 mg/kg) but no statistical increase following the lower (0.5 mg/kg)
dose. The pattern of excretion remained unchanged. Dog 101 (Figure 23)
showed an increase with both dose levels but a greater increase occurred
with the lower dose of diphenoxylate than with the higher dose, the
largest increase occurring after the 2-hr sample at Dose II (0.5 mg/kg).
Dog 102 (Figure 24), on the other hand, showed a decrease in
the amount of Macrodantin absorbed following both dose levels of
diphenoxylate. There was also a change in the pattern of drug excretion.
In the diphenoxylate studies, there appeared to be an initial immediate
increase in drug absorption which leveled off after 3 hr. In control
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FIGURE 21
Cumulative excretion of Macrodantin and Furadantin® in the urine of
Dog 103. Chemical method used to analyze urine.
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FIGURE 22
Cumulative excretion of Macrodantin 0 in urine of Dog 100 with/without
diphenoxylate. Chemical method used to analyze urine.
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FIGURE 23
Cumulative excretion of Macrodantin Q in urine of Dog 101 with/without
diphenoxylate. Chemical method used to analyze urine.
94
Arthur 2 Little, Inc
Arthur D Little Inc
50
4 - DOSE I - 2.5 mglkg diphenoxylate
42 - DOSE II - 0.5 mglkg diphenoxylate
38-
34
g 30
0
26 -
22
18 is- AconrTI
14
10- ACaoDMI& 00E I
6 - Mc inA 00SE II
1 23456 9 12 24 48
TIME (hr)
FIGURE 24
Cumulative excretion of Macrodantin( in urine of Dog 102 with/without
diphenoxylate. Chemical method used to analyze urine.
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DOSE I- 25 mg/kg diphenoxylate
44 DOSE II - 0. 5 mg/kg diphenoxylate
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FIGURE 25
Cumulative excretion of Macrodanting in urine of Dog 103 with/without
diphenoxylate. Chemical method used to analyze urine.
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<24
0
S20 -
u 16 -
J.J
DOSE I - 2.5 mg/kg diphenoxylate
8
4 DOSE II - 0.5 mg/kg diphenoxylate
2
1 2 4 6 9 12 15 18' 21 24 '48
TIME (HOURS)
FIGURE 26
Cumulative excretion of Furadantin in urine of Dog 100 with/without
diphenoxylate. Chemical method used to analyze urine.
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52
48 C FURADANTI + DOSE I
FURADANTIN' + DOSE II
40
36 -
w 32
0 28 -
S24 FURADANTI24
20 -
16 -
S12 - DOSE I - 2.5 mg/kg diphenoxylate
8
4 DOSE II - 0.5 mg/kg diphenoxylate
1 2 4 6 9 12 15 18 21 24 48
TIME (HOURS)
FIGURE 27
Cumulative excretion of Furadantin 0 in urine of Dog 101 with/without
diphenoxylate. Chemical method used to analyze urine.
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&_ a FURADANTINS DOSE II
42
38 -
34 - FURADANTI
30 -
<26 -
22 - FURADANTINA DOSE I
18 -
10
6 DOSE I- 2.5 mg/kg DIPHENOXYLATE
2 DOSE II - 0.5 mg/kg DIPHENOXYLATE
1 2 3 4 5 6 9 12 24 48
TIME (hr)
FIGURE 28
Cumulative excretion of Furadantin in urine of Dog 102 with/without
diphenoxylate. Chemical method used to analyze urine.
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52
48 DOSE I - 2.5 mg/kg diphenoxylate
44 DOSE II - 0.5 mg/kg diphenoxylate
40
36 FURADANTIe+ DOSE II
S32
" 28 FURADANTI + DOSE I
024 FURADANTI +
S20
12
8
4
.2
1 2 4 6 9 12 15 18 21 24 48
TIME (HOURS)
FIGURE 29
Cumulative excretion of Furadantin 0 in urine of Dog 103 with/without
diphenoxylate. Chemical method used to analyse urine.
100
Arthur D Little In
experiments, measuring the dog's absorption of Macrodantin only,
significant drug levels did not appear until 2 hr after the animal
received the Macrodantin
With Dog 103, 0.5 mg/kg diphenoxylate decreased absorption of
Macrodantin ~ , while 2.5 mg/kg diphenoxylate increased total drug absorption
(Figure 25). As mentioned above, Dog 103 appeared to handle both forms
of nitrofurantoin similarly. Figure 25 shows that the pattern of excretion
is similar for the control run and the run with the lower dose of
diphenoxylate. The experiment involving the higher dose of diphenoxylate
showed a disruption of that pattern, with large amounts of nitrofurantoin
found in the 6-9 and 9-12 hr samples.
Figures 26-29 illustrate the experiments with diphenoxylate and
the microcrystalline form of nitrofurantoin (Furadantin . Dogs 101 and
103 (Figures 27 and 29) show a substantial increase in the amount of
Furadantin absorbed when the animals were predosed with diphenoxylate.
The pattern of excretion is the same and both dose levels of diphenoxy-
late appear to have essentially the same effect. Dog 102 (Figure 28)
showed an increase in the level of antibiotic in the urine following the
low dose (0.5 mg/kg) of diphenoxylate but a decrease in drug level
following the higher (2.5 mg/kg) dose. As seen in Figure 27, on the
other hand, predosing with both levels of diphenoxylate in Dog 100 led
to a decrease in the amount of drug absorbed but the pattern of
excretion was the same.
Additional combination experiments were run to verify the results
obtained in the noted exception cases. Results from these experiments
confirmed the data for Dog 102 presented above but there was some
discrepancy in the repeat experiments in Dog 103. This dog originally
showed increased absorption of Furadantin with both levels of
diphenoxylate but in the Macrodantin experiments showed increased
absorption with the high dose and decreased absorption with the low dose
of diphenoxylate. The results from the repeated experiment using the
high dose of diphenoxylate were very similar to the original experiments
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TABLE 19
CUMULATIVE PERCENT OF MACRODANTIN @AND FURADANTIN EXCRETED BY DOGS WITH/WITHOUT DIPHENOXYLATE PRETREATMENT
Dog Number Macrodantin Macrodantin (100 mg total dose) plus Diphenoxylate
(100 mg total dose) Low dose (0.5 mg/kg) High dose (2.5 mg/kg)
100 11 12 18
101 15 35 28
102 16 8 8,7
103 26,22 20,40 38,40
Furadantin Furadantin (100 mg total dose) plus Diphenoxylate
0 (100 mg total dose) Low dose (0.5 mg/kg) High dose (2.5 mg/kg)
100 46 42 38
101 27 56 58
102 36 46 22
103 27 34 32
5-
but the repeat experiment using the low dose showed an increase in
absorption rather than the decrease that was first reported. Both
dose levels of diphenoxylate increased absorption of Furadantin®
and the repeated experiments showed the same results from Macrodantin.
The one experiment that indicated there was a decreased absorption of
Macrodantin was probably due to an uncontrollable variable: e.g.,
the dogs received the diphenoxylate orally at 4.00 p.m. the day before
the clearance study was run and, although they were checked to see that
the capsule was not regurgitated, this might occur.
The results of the dog study are summarized in Table 19. 14C-
Inulin clearance studies indicated that urinary functioning at the end
of this study was similar to that measured at the start. The interaction
between diphenoxylate and nitrofurantoin appears to be significant;
diphenoxylate can effect an increased nitrofurantoin absorption by
increasing the residence time of nitrofurantoin in the gut. However,
two animals pretreated with diphenoxylate showed a decreased urinary
output of nitrofurantoin. This may be due to several causes: longer
residence in the gut may permit more metabolism of nitrofurantoin by the
intestinal microorganisms; diphenoxylate may have affected biliary
secretion of nitrofurantoin.
(b) Studies in Man. The results from a study in man, the
design being similar to the study in dogs, are illustrated in Figures
30-35 and summarized in Table 20. As can be seen, the excretion of drug
in controls varied greatly from individual to individual. Three out
of the six subjects excreted more Furadantin® (48-78%) than Macrodantin
(38-62%), similar to our findings in dogs, while the reverse was true
in the other three subjects: 26-42% for Furadantin vs. 36-64% for
Macrodantin . No general statements can be made about the patterns
of excretion for early or delayed absorption also seemed to vary for each
dosage form. With the exception of two subjects, there did appear to be
a difference in the way each individual absorbed the two dose forms and
in the total amount of drug excreted. Subjects 1 and 3, however, appeared
to handle both dosage forms similarly in these respects.
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92
84
76
68
60
52
MACRODANTIN
36 -
MACRODANTIN + DIPHENOXYLATE
28 -
20 / FURADANTIN9
FURADANTIN+ DIPHENOXYLATE
12 -
4
TIME (HR)
FIGURE 30
Cumulative excretion of Macrodantin and Furadantin w i th /w i th ou t
diphenoxylate in the urine of subject No. 1. Chemical method used to
analyze urine.
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92
84
76 FURADANTIN + DIPHENOXYLATE
MACRODANTI
52 MACRODANTINV+ DIPHENOXYLATE44
L" FURADANTIN)
= 36
28
20
12
4
2 4 6 8 12 18 24
TIME (HR).
FIGURE 31
Cumulative excretion of Macrodantin and Furadantin with/without
diphenoxylate in the urine of subject No. 2. Chemical method used to
analyze urine.
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100
92
84
76
68
60 RSMACROANTI + DIPHENOXYLATE
SFURADA TIN + DIPHE XYLATE
4 -FURADANTINt
MACRODANTIN
= 36
28
20
12
4
2 4 6 8 12 18 24
TIME (HR)
FIGURE 32
Cumulative excretion of Macrodantin and Furadantin w ith /w ithou t
diphenoxylate in the urine of subject No. 3. Chemical method used to
analyze urine.
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92 URADANTIN + DIPHENOXYLATE
84 
. FURADANTIN
76
68 MACRODANTIN)
60
o 52 MACRODANTIN + DIPHENOXYLATE
644
36
W 28
20
12
4
2 4. 6 8 12 18 24
TIME (HR)
FIGURE 33
Cumulative excretion of Macrodantin and Furadantin with/without
diphenoxylate in the urine of subject No. 4. Chemical method used
to analyze urine.
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100
92
FURADANT IN + DIPHENOXYLATE
76
68 68 MACRODANTIN()
o60
S52 MACRODANTIN + DIPHENOXYLATE
S44 FURADANTIN(
28
20
12
4
2 4 6 8 12 18 24
TIME (HR)
FIGURE 34
Cumulative excretion of Macrodantin and Furadantin with/without
diphenoxylate in the urine of subject No. 5. Chemical method used to
analyze urine.
108
Arthur D Little, Inc
100
92
84
76
68 MACRODANTIN+ DIPHENOXYLATE
60
C T -FURADANTIN
,J 52 MACRODANTIN
S44 -FURADANTI + DIPHENOXYLATE
TIME (HR)
FIGURE 35
Cumulative excretion of Macrodantin  and Furadantin with/without
diphenoxylate in the urine of subject No. 6. Chemical method used to
analyze urine.
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TABLE 20
CUMULATIVE PERCENT OF MACRODANTIN AND FURADANTIN EXCRETED BY MAN WITH/WITHOUT DIPHENOXYLATE PRETREATMENT
Subject Number Macrodantin (200 mg total dose) Macrodantin plus Diphenoxylatea
1 36 27
2 60 56
3 38 54
4 60 56
5 64 50
6 52 62
Furadantin (200 mg total dose) Furadantin plus Diphenoxylatea
1 26 24
2 36 71
3 44 49
0 4 76 96
5 43 80
6 60 50
5 mg Diphenoxylate administered orally three times daily for three consecutive days prior
to dosing orally with 200 mg of the nitrofurantoin dosage form.
-t
The effect of diphenoxylate on the bioavailability of both
dosage forms of nitrofurantoin is also illustrated in Figures 30-35.
The results for each subject are depicted separately as the data varied
widely from individual to individual. In subjects Nos. 2 and 5 (Table 20) for
example, predosing with diphenoxylate led to marked increase in the
level of Furadantin in the urine while results in the other subjects
showed either no effect or a slight decrease in the level of antibiotic
absorbed.
At this point, the mechanism of action and an explanation of
the interaction between diphenoxylate and nitrofurantoin still remains
unclear. Diphenoxylate apparently can increase the overall absorption
of nitrofurantoin, given either in the macrocrystalline dosage form
or the microcrystalline dosage form to dogs. The results of combination
studies in man, however, are inconclusive. The interaction does not
appear to be significant under the conditions described, affecting
only two subjects out of six and with only one dose formulation
(Furadantin .
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TASK II - CONTINUED
B. Flurazepam
1. Azoreductase-rats X X
2. Methemoglobin-rats ........ X 'X .
3. Cytochrome P-450 ............... X
and b5
C. Methodology
1. Development X X
2. Aniline ............ X X
TASK III
Effect of diphenoxylate
on bioavailability of
nitrofurantoin
A. Studies in dog
1. Macrodantin. X X X X X X X
2. Furadantin R X X X X X
3. With diphenoxylate X X X X
B. Studies in Man
1. Macrodanti X X
2. Furadantin ... X X
3. With diphenoxylate .... ... X
C. Methodology X X
CONTINUED .
V. APPENDIX
SCHEDULE OF WORK COMPLETED - CONTENTS OF MONTHLY REPORTS FROM AUGUST 1972 TO SEPTEMBER 1973
Description of Tasks Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep
TASK I
Potential interaction between
sedative drug and nitro-
furantoin
A. Microsomal studies
1. Hexobarbital oxidase X X
2. Meperidine N-demethyl-
ase X X X
3. p-Nitrobenzoic acid
reductase X X
H 4. Cytochrome P-450
u and b 5  X X
B. Pharmacological studies
1. Chloral hydrate X X
2. Hexobarbital X X .............
3. Flurazepam ......... X ......
TASK II
Enzyme inducers and
phenazopyridine
A. Phenobarbital
1. Rats-azoreductase
and methemoglobin X X X X X
2. Rabbits-methemoglobin . X
3. Dogs - methemoglobin ..... X ... ....
CONTINUED .
Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep
TASK IV
Pharmacodynamics of
Diphenoxylate interaction
with sedative drugs
A. Pharmacological studies
1. Hexobarbital X
2 . Secobarb ital X........................ ............. .
3 . Ph en ob a rb it a l . . .. . . . . . . . . . . .. . . . .. . . .. . . . .. . . . . . . .. .. . . ..
4. Pentobarbital .........
5. Chloral hydrate ....
6. Flurazepam
B. Physiological disposition
studies
1. Hexobarbital
2. Secobarbital ..........
3. Phenobarbital X
4. Pentobarbital ....
5. Chloral hydrate
6. Flurazepam .... ..
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